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1.1 Introduction 
1.1.1 Background 
Nanomedicine can be defined as the molecular scale interventions for the diagnosis, prevention, 
and treatment of the disease using novel carrier systems that can deliver the drugs to the disease 
site. The nanomedicine is currently a rapidly growing filed as much of the interest has been taken 
in the use of nanomedicine for the diagnosis and treatment of cancer [1]. According to the World 
Health Organization (WHO), cancer is the second leading cause of deaths worldwide and is 
responsible for an estimated 9.6 million deaths in 2018. Globally about 1 out of 6 deaths are 
caused by cancer. The successful treatment of cancer depends on the several capabilities that can 
be uniquely addressed via nanomedicine. These capabilities include the smaller size, ability to 
load multiple therapeutic moieties, increased bioavailability, larger surface area, increased 
circulation time, passive targeting of the disease site using enhanced permeability and retention 
effect (EPR), the active targeting by conjugating different targeting ligands on their surface as 
well as the safety. The ability of the nanocarriers to cofunctionalize with drug payloads and 
targeting moieties enables the synthesis of multimodal systems that may provide patients with 
improved treatment efficacy [1, 2].  
1.2 Photodynamic therapy (PDT) 
PDT has been developed over the past decades into a useful treatment for several types of solid 
cancers in man. It is a very simple and minimally-invasive therapeutic approach that is being 
widely used for the treatment of cancer. The principal of PDT is based on the combination of a 
light-sensitive molecule (photosensitizer), oxygen and light. After being administered, the 
photosensitizer compound can be preferentially localized into the tumor tissue. The tumor area is 
then illuminated by a light of specific wavelength to activate the drug molecule 
(photosensitization). This photochemical process results in the subsequent generation of the 
reactive oxygen species causing cell death [3]. The phototherapy has been known to the Chinese, 
Indians, and Egyptians for over 3000 years. Niels Rydberg was the first well known modern 
scientist in the field of phototherapy who performed phototherapy on about 800 patients. He was 
awarded a Nobel prize in 1903 for his work on the use of light in the treatment of skin tuberculosis 
[4]. The history of photodynamic therapy dates back to 1888, when Marccaci, in a brief finding 
concerned with the toxic effects of plant alkaloids, reported that quinine and cinchonamine were 
found to be more toxic to the enzymes, plants and frog eggs in the presence of the light as 
compared to the dark. Although he did not provide any experimental data, it was thought that 
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apparently, he did not recognize the essential nature and the importance of this observation. The 
photosensitizing effects on the biological systems were recognized two decades later [5]. The term 
“photodynamic” was first coined by Professor Hermann von Tappeiner und Jesionek in 1904 in 
Munich. One of the Von Tappeiner’s Ph.D. student Oscar Raab found that apparent toxicity of 
acridine to the paramecium (protozoan) varied depending on the intensity of the sunlight. He also 
found that the low concentrations of acridine and other fluorescent compounds including quinine, 
eosin as well as methyl phosphine in the presence of light, sensitized the rapid killing of the 
paramecium. In his experiments, he demonstrated that these substances had no effect in the dark 
and also the light alone had no effect. Raab’s observations were backed by the C. Ledoux-Lebards 
(1902) findings. His observations manifested that eosin killed paramecia more effectively in open 
flasks as compared to the closed bottles. On the basis of these observations, he postulated that the 
presence of oxygen was necessary for the photoinactivation of paramecia. These investigations 
triggered the discovery of many photosensitizing compounds such as tetrapyrroles including 
hematoporphyrin and chlorophyll, xanthenes, thiazines, and anthracenes, etc. All of these 
discovered compounds were fluorescent and needed the presence of oxygen for their action. It 
was also investigated that a variety of biological organisms or systems such as enzymes, toxins, 
proteins, viruses, protozoa, bacteria, fungi and cells of higher animals can be destroyed by 
sensitization using light [5, 6].  
 
Figure 1. Historical developments of photodynamic therapy (1900-present) [7]. 
1.2.1 Mechanism of photodynamic therapy:  
The photodynamic therapy typically consists of two processes including light absorption and the 
energy transfer. Generally, the photosensitizer (PS) in the ground state contains two electrons 
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having an opposite spin in the low energy molecular orbital. This ground state is termed as a 
singlet state. When irradiated by the light of a specific wavelength, one of the electrons after 
absorption of the light in the form of photons, is excited into a higher energy orbital. The electron 
keeps its spin in this high energy orbital and is termed as an excited singlet state. This is a very 
short-lived state (usually nanoseconds) during which the excited electron (species) can lose its 
energy by internal conversion into heat or by emitting light in the form of fluorescence. The 
excited singlet state may also undergo intersystem crossing resulting in the inversion of the 
electron spin. This state is relatively long-lived (microseconds) and is termed as an excited triplet 
state in which both the electron spin in a parallel confirmation. This PS excited triplet state may 
then undergo two kinds of reactions.  
Type I reaction involves the direct reaction of the PS with substrates such as cell membrane or 
any molecule within the cell thereby transferring a proton or an electron to form an anion or cation 
radical respectively. These radicals then further react with the tissue oxygen to produce reactive 
oxygen species (ROS).  
Type II reactions involve the transfer of energy from excited triplet PS state directly to the 
molecular oxygen causing the formation of excited singlet oxygen state [8].  
Type I reactions mostly involve the transfer of the electron from the excited triplet PS to molecular 
oxygen (monovalent reduction) resulting in the initial production of superoxide anion. These 
superoxides do not cause so much oxidative damage to the cells as they are not reactive to the 
biological systems. These superoxides may act one of either ways or all of them simultaneously: 
A) These superoxides may react themselves in the presence of superoxide dismutase (SOD) to 
form hydrogen peroxide (H2O2) and oxygen. This hydrogen peroxide is necessary for the 
functioning of the cellular enzymes. This hydrogen peroxide (H2O2) can readily cross the cell 
membranes and cannot then escape the cell. Inside the cell, it acts as reducing agents for the 
production of hydroxyl radical (OH.). This process is called a Fenton reaction and is explained 
below.  
B)  The superoxide also causes the reduction of metal ions (e.g. ferric ion Fe3+) by donating one 
electron. These reduced metal ions then act as a catalyst for the conversion of intracellular H2O2 
into the hydroxyl radical (OH.) by causing the breakage of the oxygen-oxygen bond of hydrogen 
peroxide (H2O2) thus producing a hydroxyl radical (OH.) and hydroxide ion (OH). 
C) The superoxide may also simultaneously react with hydroxyl radical (OH.)  to form singlet 
oxygen.  
D) Alternatively, the superoxide may also react with nitric oxide radical (NO-) to produce 
peroxynitrite (OONO-), a highly reactive oxidizing molecule [9]. 
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Due to very short half-life and high reactivity of the singlet oxygen and free radicals produced 
during ROS production, the cell structures and the molecules in their close proximity are directly 
affected and subsequently destroyed by PDT. Both of these reactions can occur simultaneously. 
The ration between the processes is mainly dependent on the type of PS used, the amount of tissue 
oxygen and the concentration of the substrate involves. 
 
Figure 2. Schematic representation of photochemical and photophysical mechanisms of PDT [8]. 
1.2.2 Characteristics of ideal photosensitizer 
The characteristics of an ideal photosensitizer have been discussed by various authors in the 
literature. Briefly, 
1. They should have a low level of dark toxicity to both human and experimental animals and 
should have a low incidence of administrative toxicity. 
2. They should absorb light in the red or infrared wavelengths in order to penetrate the tissue as 
the absorption bands at shorter wavelengths have less tissue penetration and are more likely 
to lead to skin photosensitivity (the power in the sunlight drops off at λ > 600nm) while the 
absorption bands at wavelength (> 800nm) means that the photons will not have sufficient 
energy for the PS triplet state to transfer energy to the ground state oxygen molecule to excite 
it to the singlet state. 
3. They should have relatively high absorption bands (> 20,000-30,000 M-1cm-1) to minimize 
the dose of photosensitizer needed to achieve the desired effect. 
4. They should have high selectivity for the tumor tissue as compared to the healthy tissue. 
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5. The synthesis of the PS should be relatively easy and the starting materials readily available 
to make large scale production feasible. 
6. The photosensitizer should be a pure compound with constant composition and stable shelf 
life and be ideally water-soluble or soluble in the harmless aqueous solvent mixture. It should 
not aggregate in the biological environment as this reduces its photochemical efficiency. 
7. The pharmacokinetic elimination from the patient should be rapid. i.e. less than one day to 
avoid the necessity for post-treatment protection from light exposure and prolonged skin 
sensitivity. 
8. A short interval between injection and illumination is desirable to facilitate outpatient 
treatment that is both patient-friendly and cost-effective [10, 11]. 
1.2.3 Photodynamic therapy to the tumor cells: 
The effects of the reactive oxygen species produced in the tissues depend on the type and 
concentration of the photosensitizer used, the conditions of irradiation, concentration of the 
oxygen in the tissue as well as the type of cancer cell. Since the half-life of the highly reactive 
singlet oxygen in biological systems is less than 40 ns and thus has a radius of action of only about 
20 nm, the location of the PS within the cell determines which cell compartment is primarily 
damaged. This has a significant impact on the efficiency of PDT and the nature of cell death. 
Damage to structures such as mitochondria, lysosomes, endoplasmic reticulum (ER), plasma 
membrane or nucleus can lead to apoptosis, necrosis or autophagocytosis via various signal 
transduction pathways. Before the PS can be taken up by the tumor cells after intravenous 
administration, it first has to be distributed in the intravascular space and through the vessel walls 
into the tumor interstitium. Depending on the "drug-light interval" (distance between the 
application of the PS and the radiation), the PS is still in the vessels or it has already migrated into 
the interstitial space. Depending on the time of irradiation, in addition to the cells, the tumor 
vessels may also be the target structure of PDT. This leads to the destruction of endothelial cells 
of the vessel wall as well as to rheological changes such as increasing the viscosity resistance or 
the intravascular pressure. The consequences are thrombosis by activation of platelet aggregation, 
increased permeability of the vessels, bleeding, vessel constriction or blood stasis. The lack of 
oxygen and nutrients can, therefore, lead to necrosis of the tumor tissue. Furthermore, PDT is the 
trigger for a local inflammatory response that results in an antitumoral immune response. PDT 
leads to the direct release of inflammatory mediators and cytokines, including interleukins (IL) 
such as IL-1β, IL-2, IL-6, IL-10 and tumor necrosis factor α (TNF-α). This is followed by the 
immigration of immune cells such as neutrophils, mast cells, and macrophages. In addition, tumor 
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antigens and so-called "damage-associated molecular patterns" (DAMPs) are released. These act 
as immune stimulators as soon as they are expressed or released on the surface of damaged cells, 
and activate both the innate and adaptive immune systems. The antigen-presenting dendritic cells 
(DC) are activated and migrate to the local lymph nodes. There they lead to the activation of T 
helper cells and cytotoxic T cells. As a result, the immune response not only reaches the irradiated 
lesion but also tumor metastases. These three mechanisms of action of PDT, the direct 
cytotoxicity, the thromboembolic effect, and the immune response are mutually dependent. 
1.3 Nanocarriers for cancer therapy 
The nanocarriers are the nanosized materials usually with a diameter ranging from 1-1000nm that 
can carry multiple drugs or/and imaging agents. Due to their high surface area to volume ratio, it 
is possible to achieve high ligand density on the surface for targeting purposes. Nanocarriers can 
also be used to increase the local drug concentration by carrying the drug within and controlling 
its release when attached to the targets. Currently, natural and synthetic polymers, as well as lipids, 
are typically used materials for the construction of drug delivery vehicles. Generally speaking, the 
family of the nanocarriers includes lipid-based nanocarriers such as micelles and liposomes, 
carbon nanotubes, polymeric nanoparticles, polymer conjugates as well as the gold nanoparticles 
including nanoshells and nanocages. These nanocarriers have been explored for a number of 
therapeutic applications such as imaging, drug delivery, photothermal ablation of tumors, 
detection of apoptosis and radiation sensitizers [12]. 
1.3.1 Polymeric nanoparticles  
Polymers are the most widely explored materials for the preparation of nanoparticles-based drug 
delivery systems. Nanoparticles have become an important area of research in the pharmaceutical 
sciences as they are able to deliver a variety of drugs for sustained periods of time. The history of 
the nanoparticle dates back to 1979 when Couvreur and his co-researchers prepared the 
polyalkylcyanoacrylate nanoparticles and discussed the adsorption/attachment of the 
antineoplastic drugs (i.e. methotrexate and dactinomycin) on the nanoparticles. They also 
described the release kinetics of the drug from the nanoparticles and elaborated their distribution 
and efficacy in the tumor model. These studies served as the basis for further development of the 
nanoparticles-based delivery of the drugs.  This was followed by the preparation and initial 
clinical testing of Doxorubicin loaded nanoparticles [12]. Different natural polymers such as 
proteins and polysaccharides (e.g. collagen, chitosan) and synthetic polymer are used for the 
preparation of the nanoparticles. Most widely used synthetic polymers include poly (glycolic acid) 
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(PGA), poly (lactic acid) (PLA) and their copolymers i.e. poly(lactide-co-glycolide) (PLGA). 
Nanoparticles prepared from these polymers are well known for their subcellular size, 
biocompatibility with the tissue and cells, and biodegradability through the natural body 
pathways. Apart from this, these nanoparticles are stable in the blood, non-toxic, non-
inflammatory, non-thrombogenic, non-immunogenic and applicable to various molecules such as 
drugs, proteins, peptides or nucleic acid [13]. These polymeric nanoparticles also give the 
advantage of manipulating the rate of drug release by varying the polymer ratio during the 
preparation process. The drug release occurs in a controlled manner through swelling followed 
diffusion through the polymer matrix, through surface or bulk erosion or in response to the local 
environment. The polymeric nanoparticles have been synthesized using various methods 
depending upon the type of drug to be encapsulated and the need for its application. The most 
commonly used method for the preparation of polymeric nanoparticle is the emulsion-solvent 
evaporation technique. This method has been successfully employed for the entrapment of 
hydrophobic drugs but shows poor results for the encapsulation of bioactive compounds that are 
hydrophilic in nature. Briefly, the solvent evaporation is carried out by dissolving the polymers 
and drug into a common organic solvent. Most commonly dichloromethane, acetone and ethyl 
acetate are used for PLGA copolymers. Then emulsion is then prepared by adding the aqueous 
phase containing a surfactant into the polymeric solution. The formation of the nanosized polymer 
droplets is then induced by sonication or high shear homogenization. In the end, the nanoparticles 
are then collected by centrifugation or by lyophilization [13, 14].     
 
Figure 3. Different types of biodegradable nanoparticles. Based on the structure, they can be 
classified as nanocapsules or nanospheres. The manufacturing methodology varies according to 
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the type of nanoparticles. The bioactive compounds can be entrapped within the polymer matrix 
or can be absorbed on the surface [13]. 
1.3.2 Liposomes as drug carriers 
The word liposomes have been derived from the Greek words; ‘Lipos’ means fat and ‘Soma’ 
means body. Liposomes are the concentric bilayer vesicular structures composed of phospholipids 
and formed when these lipids are exposed to an aqueous environment. Liposomes were first 
accidentally discovered in 1964 by a British hematologist Dr. Alec Bangham at the Babraham 
institute of Cambridge. The liposomes were discovered when Dr. Bangham and his co-worker Dr. 
Horne were testing a new electron microscope at the institute by adding a negative stain to the dry 
phospholipids leading to swollen phospholipid system. Investigations of their workgroup laid the 
stone of a new horizon for the development of new lipid-based drug delivery systems [15]. Within 
a dew year, a variety of enclosed lipid bilayer structures, initially described as ‘Banghasomes’ and 
later on ‘liposomes’ were prepared. Liposomes are the novel carrier systems that have been 
investigated more than any other delivery system as a result of their various forms. 
Glycerophospholipids are the most prominent lipids used for the preparation of liposomes. These 
lipids generally consist of a glycerol backbone esterified at C1 and C2 with two fatty acid chains 
with 10-24 carbon atoms. Each fatty acid chain may also contain 0-6 double bonds. The chain 
length and the degree of unsaturation determine the permeability and phase behavior of the lipids. 
These fatty acid chains form the hydrophobic part of the lipid molecule. At C3 the glycerol is 
esterified with alcohol via a phosphodiester linkage to form the hydrophilic part of the lipid. When 
dispersed in an aqueous medium, these lipids form spherical, vesicle-like structures by aligning 
themselves in such a way that the polar head (hydrophilic) group faces the aqueous region while 
non-polar part (hydrophobic tails) face each other and is shielded by the polar fraction. The 
unfavorable interactions between lipid-lipid and/or lipid-water molecules and large free energy 
between hydrophilic and hydrophobic environment leads to the formation of bilayer vesicular 
structure in order to achieve a thermodynamic equilibrium and minimum surface tension in the 
aqueous phase [16]. 
The liposomes can be classified in a number of ways. Generally speaking, they can be classified 
on the basis of the size as well as the number of bilayers. They are classified as small unilamellar 
vesicles (SUVs), large unilamellar vesicles (LUVs), multilamellar vesicles (MLVs) and 
multivesicular system (MVS). Based on the composition of the lipid used they can be classified 
as conventional liposomes (CL), cationic liposomes, pH-sensitive liposomes, thermosensitive 
liposomes, immunoliposomes, and long-circulating liposomes. They can also be classified on the 
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basis of the method of preparation as reverse-phase evaporation vesicles (REVs), ether injection 
vesicles (EIVs), French press vesicles (FPVs) and dehydrated rehydrated vesicles (DRVs). 
The unique ability of the liposomes to entrap both the lipophilic and hydrophilic drugs enables a 
wide range of compounds to be encapsulated by these vesicles. The hydrophilic compounds are 
encapsulated into the aqueous core while the lipophilic molecules are entrapped into the lipid 
bilayer membrane. Additionally, the presence of the large aqueous core and the biocompatible 
nature of the phospholipid surface, these vesicles can also be used for the delivery of large 
macromolecules such as proteins, imaging agents as well the DNA. As nanocarriers, the liposomes 
offer several advantages including biocompatibility, ability to carry drug payloads, the capacity 
of self-assembly and a wide range of physicochemical and biophysical properties that can be 
modified to control their biological characteristics. They also protect the encapsulated compound 
from pre-mature inactivation and degradation. Liposomes are generally considered to be non-
toxic, pharmacologically inactive and mimic the normal plasma membrane characteristics [17]. 
One of the major drawbacks of conventional liposomes is the physical and chemical stability as 
well as the rapid clearance from the blood circulation due to the adsorption of the plasma proteins 
on their surface (opsonization). This can be avoided by the surface coating of the liposomes with 
a hydrophilic carbohydrate, polymer or a lipid derivative of polyethylene glycol (PEG). Also, the 
composition of the lipid can be modulated to obtain prolonged circulatory half-life (stealth 
liposomes) [15].   
 
Figure 4. The structure and possible surface modifications of the liposomes [18]. 
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1.3.3 Lipid coated polymeric nanoparticles 
Lipid coated biodegradable nanoparticles (LCNPs) are the lipid-polymer hybrid systems 
comprising of polymeric nanoparticle core-shell enveloped by the single or multiple lipid layers 
thereby melding the biomimetic properties of long-circulating lipid vesicles as well as the 
mechanical advantages of the polymeric nanoparticles to enable an efficient drug delivery system. 
These nanoscopic architectures use the single nanocarrier system to combine the multiple 
therapeutic modalities delivering the payload at the desired tumor site and giving rise to a 
synergistic effect. These hybrid systems are advantageous over conventional carrier systems in 
terms of controllable size, tunable drug release properties, high drug loading, surface functionality 
as well the serum stability [19]. These lipid-polymer hybrid nanoparticles (LPHNs) as termed as 
lipoparticles are the superior delivery systems because these novel systems can mitigate the 
limitations associated with the conventional delivery systems (i.e. liposomes and polymeric 
nanoparticles).  
Structurally, these lipoparticles are solid, submicron particulate systems consisting of at least two 
components. i.e. polymer and the lipid. The first building block is polymeric core, generally 
composed of a biodegradable hydrophobic polymer, that acts as carrier for poorly water-soluble 
drugs and imparts controlled drug release properties to the system. The commonly used polymers 
include the polylactide-co-glycolide (PLGA), polycaprolactone (PCL), dextran and albumin. 
These polymers are the most common choices because of their biocompatibility, nontoxicity, 
biodegradability, as well as their previous use in the various FDA, approved products. The second 
component is the shell or outer corona that uniformly surrounds the polymeric core. Commonly 
used lipids for the outer shell include, cationic, anionic and zwitterionic lipids such as 1,2 -
dipalmitoyl -sn-glycero-3-phosphocholine (DPPC), 1,2 -dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE), 1,2-dioleoyloxy-3-trimethylammonium propane  (DOTAP), 1,2 -
dipalmitoyl -3 -trimethylammonium -propane (DPTAP), lecithin as well as the hydrophilic 
substrates such as PEG-lipid conjugates. This layer allows the LPHNs to evade the uptake by the 
immune system and also imparts the long-circulating characteristics [20]. Various bioactive 
compounds such as drugs, proteins, genes, and different targeting legends can be entrapped, 
absorbed or covalently attached to the hybrid system. Additionally, a lipid monolayer can be 
deposited at the interface of the core and shell as a third component. This layer reduces the water 
penetration of the water and diffusion of the drug from the core. This, in turn, increases the 
encapsulation efficiency and alters the rate of drug release. 
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The Lipoparticles are generally prepared simply by mixing the polymeric nanoparticles and 
liposomes together in order to form lipid-polymer complexes in which a phospholipid bilayer 
(shell) completely covers the surface of the polymeric nanoparticle (core). The space between the 
core and shell is occupied by the water or aqueous buffer. Oppositely charged phospholipids are 
used to promote the electrostatic interactions between the polymeric core and lipid shell. Other 
than the two-step method for the preparation of lipoparticles, some other methods include the 
single-step method, modified solvent extraction/evaporation method and modified 
nanoprecipitation method [19, 21].  
Some of the major advantages of the lipoparticles include the synergistic delivery of multiple 
biomolecules, improved encapsulation of hydrophobic drugs, tunable drug release profiles, 
mechanical stability, biocompatibility, narrow size distribution, serum and storage stability over 
the prolonged time periods as well as the high specific surface area [1]. 
1.4 Aims and objectives  
The present study was aimed at the development of a novel integrated system comprising of lipid 
enveloped biodegradable nanoparticles (lipoparticles) for the combined chemo-photodynamic 
therapy. The developed lipoparticles were capable of delivering two pharmacologically active 
moieties simultaneously to the cancer cells. This multi-drug therapy is advantageous over the 
conventional therapies because a single nanocarrier system can be used to co-localize the different 
therapeutic moieties in the cancer cells thereby increasing the treatment efficacy, potentially 
overcoming the drug resistance and reducing the side effects to the neighboring tissues. 
The key aspects covered in this work are divided into following parts: 
1. Temoporfin (mTHPC) is a lipophilic compound that exhibits very poor water solubility as 
well as low permeability through the biological membranes (BCA class IV). In addition 
to these, poor bioavailability is an additional challenge to its applications in cancer 
therapeutics. The initial part of the work would be focused on the development of different 
liposomal formulations using a broad range of lipid combinations encapsulating mTHPC 
to enhance the liposomal stability, prolonged circulation time and to compare the 
photodynamic effect in Ovarian carcinoma cells (SK-OV-3).  
2. The second part of the work would be directed towards the preparation of PLGA 
nanoparticles encapsulating Pirarubicin (THP) as a model anticancer drug. Being the 
potent hydrophobic molecule, the pharmacokinetic parameters of THP can be modified by 
encapsulating it into a nanoparticulate system thus reducing the side effects and increasing 
13 
 
the efficacy of the system Two different size nanoparticles would be prepared to evaluate 
their differential parameters. 
3. Based on the preliminary studies, the later part of the studies would be aimed at the surface 
modification of the THP nanoparticles by coating the best performing mTHPC loaded 
liposomes over them thereby combining two different therapeutic modalities within a 
single nanocarrier. 
4. Optimizations and detailed physicochemical evaluations of the prepared formulations by 
established techniques including size and charge distribution measurements. 
Comprehensive structural and morphological characterizations by different microscopic 
techniques including atomic force microscopy and electron microscopic studies.  
5. Establishing the in vitro cell culture studies including ROS, intracellular uptake, comet 
assay as well as stability studies. In ovo studies using the CAM model as alternative in 
vivo model would be employed for establishing the efficacy of the prepared liposomes. 
6. Acute in vivo cytotoxicity assessment to evaluate the biocompatibility of the system 
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2.1 Materials 
2.1.1 List of materials and devices:  
Materials and Devices Source 
AFM Probes; NSC14/Al BS & 
NSC16/Al BS 
Mikromasch, Tallinn, Estonia 
Ampicillin Sigma Aldrich Chemie GmbH, Taufkirchen, Germany 
Atomic force microscope; 
NanoWizard® 3 
JPK Instruments AG, Berlin, Germany 
Autoclave, Tuttnauer 3850 ELC Tuttnauer GmbH, Linden, Germany  
Bath sonicator; Transonic Digital S Elmasonic P30H Schmidbauer GmbH, Singen, 
Germany 
Cell counter R1 Olympus Corporation, Tokyo, Japan 
Cell counting slides R1-SLI Olympus Corporation, Tokyo, Japan 
Cell culture lysis reagent Promega GmbH, Mannheim, Germany 
Centrifugation machine II   Centurion Scientific, Chichester, UK 
Centrifuge 5418 Eppendorf AG, Hamburg, Germany 
Chitosan Sigma-Aldrich, Taufkirchen, Deutschland  
Cholesterol   Sigma Aldrich Chemie GmbH, Taufkirchen, Germany  
Chlorpromazine Alfa Aesar GmbH & Co. KG., Karlsruhe, Germany 
Coagulation analyzer TECO GmbH, Neufahrn, Germany 
CO2 incubator, HeraCell Heraeus GmbH & Co. KG, Hanau, Germany 
Confocal laser scanning microscope; 
LSM 700 
Carl Zeiss Microscopy GmbH, Jena, Germany 
Constant power supply LKB 2197 LKB Bromma, Bromma, Sweden 
Disposable folded capillary cell; 
DTS1060 
Malvern Instruments Ltd, Malvern, UK 
DMEM Capricon Scientific, Ebsdorfergrund, Germany 
DMSO; ≥ 99% Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
DOPE, DOTAP, DPPC, DPPE-
mPEG5000, And DPPG 
Gift samples from Lipoid AG, Steinhausen, Switzerland 
Electrophoresis chamber Thermo Electron GmbH, Ulm, Germany 
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Ethanol Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Ethyl acetate VWR International, Darmstadt, Germany 
Extruder; Avanti Mini   Avanti Polar Lipids Inc., Alabaster, USA  
Female BALB/c, mice National Institute of Health, Islamabad, Pakistan  
Fetal bovine serum Capricon Scientific, Ebsdorfergrund, Germany  
Fertilized eggs Mastkükenbrüterei Brormann, Rheda-Wiedenbruck, 
Germany  
Filipin III Sigma Aldrich Chemie GmbH, Taufkirchen, Germany 
Formaldehyde Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Fluorescence microscope I CKX-53 Olympus Corporation, Pennsylvania, USA 
Fluorescence microscope II EVOS FL cell imaging system, Thermo Scientific, San 
Diego, USA  
Freeze drier; Christ Beta I Martin Christ Gefriertrocknungsanlagen GmbH, 
Osterode am Harz, Germany 
H2DCFDA Sigma Aldrich Chemie GmbH, Taufkirchen, Germany 
Hatching incubator; Ehret KMB 6 Dipl. Ing. W. Ehret GmbH, Emmendingen, Germany  
Hematology analyzer Icon-3, Norma Instruments, Budapest, Hungary 
Heparin sodium salt   Thermo Fischer Scientific, Dreieich, Germany  
IMDM   Capricon Scientific, Ebsdorfergrund, Germany  
Antibiotic/antimycotic solution  Capricorn Scientific GmbH Ebsdorfergrund, Germany  
Laminar flow hood; Labogene LMS GmbH &Co.KG, Brigachtal, Germany 
LED device (prototype) Lumundus GmbH, Eisenach, Germany 
Liquid CO2   Praxair Deutschland GmbH, Düsseldorf, Germany 
Low melting agarose   Carl Roth GmbH & Co. KG, Karlsruhe, Germany  
Microplate reader FLUOstar® Optima BMG Labtech, Ortenberg, Germany 
Magnetic stirrer; MCS 66 CAT Scientific, Paso Robles, USA  
Megafuge 1.0 R Thermo Fischer Scientific, Dreieich, Germany 
Mounting medium; FluorSave™ Calbiochem Corporation, San Diego, USA  
MTT dye Sigma Aldrich Chemie GmbH, Taufkirchen, Germany  
Microscopy Slides Carl Roth GmbH & Co. KG, Karlsruhe, Germany  
Nano-100 Micro-spectrophotometer Hangzhou Instruments Co., Ltd, Hangzhou, China 
Normal melting agarose Carl Roth GmbH & Co. KG, Karlsruhe, Germany  
Orbital shaker KS4000 IC IKA Werke GmbH & Co. KG Staufen, Germany 
17 
 
Petri dishes; Tissue culture grade Sarstedt AG & Co., Nümbrecht, Germany 
Pirarubicin; THP (≥ 99%) Selleckchem, Munich, Germany 
PLGA Resomer® RG 503H Evonik Nutrition & Care GmbH Essen, Germany  
Pneumatic egg puncher Schuett Biotech, GmbH, Göttingen, Germany 
Polycarbonate membranes Whatman plc, Buckinghamshire, UK 
PURELAB flex II dispenser ELGA LabWater, High Wycombe, UK 
PVA; Mowiol® 4-88 Kuraray Europe GmbH Frankfurt, Germany  
Rotary evaporator; Laborota efficient 
4000 
Heidolph Instruments GmbH & Co. KG, Schwabach, 
Germany  
Serum biochemical marker analyzer Micro lab 300, Merck, Germany 
Shaking incubator; IKA KS4000 IC IKA Werke & Co. KG, Staufen, Germany 
SK-OV-3 cell line ATCC®, Manassas, USA  
Stereomicroscope   Stemi 2000-C, Carl Zeiss GmbH, Germany 
Sodium acetate (> 98.5%) Carl Roth GmbH + Co. KG Karlsruhe, Germany  
Sodium chloride (> 99.8%) Carl Roth GmbH + Co. KG Karlsruhe, Germany  
SYBR® safe DNA gel stain Thermo Fischer Scientific, Dreieich, Germany 
Temoporfin; mTHPC (≥95%) Cayman chemicals, Hamburg, Germany 
TEClot aPTT-S Kit TECO GmbH, Neufahrn, Germany 
Trypsin-EDTA,  Capricorn Scientific GmbH Ebsdorfergrund, Germany  
Triton™ X-100 Sigma Aldrich Chemie GmbH, Taufkirchen, Germany 
Transmission electron microscope;  (TEM) JEM-1400, JEOL Ltd., Tokyo, Japan 
Uranyl acetate Sigma Aldrich Chemie GmbH, Taufkirchen, Germany 
Vacuum pump; SC 920 KNF Neuberger GmbH, Freiburg, Germany 
Water bath Kottermann GmbH & Co. KG, Hänigsen, Germany 
Zetasizer Nano ZS Malvern Instruments Ltd, Malvern, UK 
0.2 μm PES syringe filters Sarstedt AG & Co. KG, Nümbrecht, Germany  
15 mm cover slips Gerhard Menzel B.V. & Co. KG, Braunschweig, 
Germany 
6-well plates; TC Standard. F Sarstedt AG & Co. KG, Nümbrecht, Germany 
12-well plates; Nunclon Delta Nunc GmbH & Co. KG, Wiesbaden, Germany 
96-well microtiter plates, Nunclon 
Delta 
Thermo Fischer Scientific, Dreieich, Germany  
5 ml glass vials Schott AG Müllheim, Germany  
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2.1.2 Solvents 
All the solvents were of HPLC or analytical grade and were used without any further 
modifications. Ultrapure water from PURELAB flex -IV equipped with a point of use biofilter 
(ELGA LabWater, UK) was used for all the experiments. The phosphate-buffered saline (PBS: 
pH 7.4) with and without Ca2+/ Mg2+ were prepared in the lab, sterile filtered and stored at 4 ºC 
for further use. 
2.1.3 Cell culture 
A wild type human ovarian adenocarcinoma (SK-OV-3) cell line was procured from American 
type culture collection (ATCC®, Manassas, USA). The cells were cultivated at 37°C and 7% CO2 
under humid conditions in a high glucose DMDM supplemented with 10% FCS and MEM-non-
essential amino-acids (Gibco™, Thermo-Fischer). The cells were grown as a monolayer and 
passaged to 80 % confluency.  
2.1.4 Chorioallantoic membrane  
The chick chorioallantoic membrane (CAM) assay was conveniently used as an alternative in-
vivo model. For this purpose, specific pathogen-free fertilized chicken eggs each weighing 50-60 
g were used. 
2.1.5 Lipids 
2.1.5.1 DPPC 
DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine) is a saturated, amphiphilic phospholipid 
molecule consisting of two non-polar palmitic acids (fatty acid) chains attached to a 
phosphocholine polar head group. It has a molecular weight of 734.039 g/mol. It is found in 
solid/gel phase at 37 °C (human body temperature) but exists as a liquid phase at a glass transition 
temperature (Tg) of 41 
°C. For a free-floating fully hydrated DPPC, four distinguished phases can 
be described as subgel, gel, ripple and fluid phase. Based on the polar-non polar interactions, it 
can arrange itself from a planner bilayer structure to a spherical bilayer (i.e. liposomes) or unilayer 
(i.e. micelles) vesicular structure. DPPC is zwitterionic in nature because of the presence of 
negative charge on the phosphate group and positive charge on the quaternary ammonium group. 
It is the most widely found lipid in the pulmonary surfactants, eggs and lipid bilayer making up 
the plasma membranes [22, 23]. For this study, DPPC with a purity of 99%, was used as a major 
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vesicle forming lipid. The lipid was dissolved in a mixture of chloroform: methanol (2:1 v/v) to 
get a stock solution of 10mg/mL of the lipid and stored at -20 °C until further use. 
 
Figure 5. Chemical structure of DPPC 
2.1.5.2 DPPE-mPEG5000 
DPPE-mPEG5000 (1,2 -dipalmitoyl- sn- glycero-3-phospho ethanolamine-N [methoxy 
(polyethylene glycol)- 5000] is a saturated lipid having a covalent bond between the phospholipid 
and linear PEG chain. DPPE-mPEG5000 has a molecular weight of 5745.030 g/mol with a phase 
transition temperature (Tm) of 63 ºC. The inclusion of the PEG-PE conjugates in the drug carrier 
systems results in the drastically prolonged circulation times. This is due to the increase stearic 
repulsion of the PEG-coated particles leading to the particle-particle interaction, therefore causing 
the inhibition of the adsorption of various opsonins. This in turn also increases the biological 
stability of PEG conjugated carrier systems [24]. The PEG-PE lipid when added at higher molar 
ratios (above the bilayer saturation concentration) in the formulations, induce the formation of 
mixed micelle structure. Depending on the lipid composition of the sample, these micelles may 
adopt either a discoidal or threadlike shape [25]. For this study, DPPE-mPEG5000 with a purity 
of 99%, was used. The lipid was dissolved in a mixture of chloroform: methanol (2:1 v/v) to get 
a stock solution of 10mg/mL of the lipid and stored at -20 °C until further use. 
 
Figure 6. Chemical structure of DPPE-mPEG5000 
2.1.5.3 DOTAP 
DOTAP (1,2-dioleoyl-3-(trimethylammonium)-propane) is an unsaturated, synthetic cationic 
lipid composed of a quaternary amine as a head group attached to the two oleoyl tail chains with 
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a molecular weight of Mw= 698.542 g/mol. The racemic mixture of the DOTAP has a phase 
transition temperature (Tm) of less than 5 °C [26]. Because of its cationic nature, it is a widely 
used lipofection agent in liposomal transfection studies. The incorporation of unsaturated lipids 
(i.e. DOTAP) could also accelerate light-triggered drug release via liposomal carrier systems [27]. 
It is also generally observed that increasing DOTAP share causes an increase in membrane 
fluidity, which peaks at 75% DOTAP content and then slightly decreases again [28]. A ≥ 90% 
pure DOTAP was used for this study. The lipid was dissolved in a mixture of chloroform: 
methanol (2:1 v/v) to get a stock solution of 10 mg/mL of the lipid and stored at -20 °C until 
further use. 
 
Figure 7. Chemical structure of DOTAP 
2.1.5.4 DPPG 
1,2-dipalmitoyl-sn-glycero-3-phosphoglycerol (DPPG) is an anionic, saturated phospholipid 
comprising of two palmitoyl chains attached to a glycerol backbone. DPPG has a molecular 
weight of 744.952 g/mol with a glass transition temperature of 41 ºC (Similar to the DPPC). DPPG 
in combination with other lipids is used to increase the intracellular uptake of the drug-loaded 
nanocarrier systems. In our study, DPPG with a purity of 99% was used was generously donated 
by Lipoid (Steinhausen, Switzerland). A stock solution of 10 mg/mL lipid was prepared by 
dissolving it in a mixture of chloroform: methanol (2:1). The stock solution was preserved at -20 
°C stored in a glass vial until further use. 
 
Figure 8. Chemical structure of DPPG 
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2.1.5.5 TEL 
The plasma membrane of the archaea is rich in tetraether lipids (TELs) and diphytanylgylcerol 
diether, also known as archeols [29]. TELs are the basic building blocks of the cell membrane of 
the archaea of the genus Sulfolobus acidocaldarius and Thermoplasma acidophilus. The special 
structure of the tetraether lipids shields the cell interior from the external influences and ensures 
increased rigidity of the cell membrane. Archaeal TELs (polar lipid fraction E; PLFE) isolated 
from Sulfolobus acidocaldarius is a mixture of two lipids, 90% glycerol dialkyl nonitol tetraether 
(GDNT/ calditolglycerocaldarchaeol) and 10% glycerol dialkyl glycerol tetraether (GDGT/ 
caldarchaeol). These two basic types of TELs consist of two biphytanyl chains (C40), each of 
which is attached via ether bonds to a glycerol molecule. Both carry at one end a phosphatidyl 
myo inositol group. At the other end, GDNT has an annular nonitol group (calditol group) linked 
to β-D glucose, while GDGT has a β-D galactosyl-D glucose group [30]. The phytanyl 
hydrocarbon chains (C40) contains cyclopentane rings in their structure. As the number of 
cyclopentane rings is increased, it results in the tightening of the membrane packing. The bipolar 
tetra-lipids form monolayers within cell membranes, by completely traversing the membrane 
rather than being a double membrane, as in conventional lipids. It is believed that the presence of 
a hydrogen network between the head groups in the TELs and presence of higher molar fractions 
of the TELs in the membranes results in the greater rigidity and increased temperature. These 
extraordinary stability characteristics of the TEL against a variety of physical and biochemical 
stressors have provided the basis for using these lipids to develop various technological 
applications e.g. stable liposomal formulations, nanoparticles for targeted imaging and therapy 
[31]. 
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Figure 9. Chemical structure of GDGT (caldarchaeol) and GDNT (calditolglycerocaldarchaeol) 
present in polar lipid fraction E (PLFE). The bipolar tetraether lipids in the PLFE were isolated 
from S. acidocaldarius [32].  
2.1.5.6 Cholesterol  
Sterols are the vital constituents of neutral membranes playing a critical role in the regulation of 
membrane fluidity. Cholesterol is the most common sterol in the mammalian cell membrane, 
being present in the several liposome-based therapies approved by FDA. The cholesterol 
molecules are natural phospholipids with a tricyclic ring having a double bond at the position 5, 
6 and 3 beta-hydroxy groups [33]. It has a molecular weight of 386.654 g/mol. Cholesterol acts 
to maintain transfection in the presence of serum by improved binding and uptake by the cells. 
Inclusion of the cholesterol in the liposomes also tends to increase the stability and half-life of the 
neutral and anionic liposomes in the blood circulation by causing changes in the fluidity of the 
membrane. This is attributed to the fact that less protein became bound to the cholesterol 
containing liposomes which in turn reduced the liposomal uptake by the reticuloendothelial 
system (RES) [34]. It also reduces the leakage of water-soluble drugs in the liposomal membrane 
by reducing the permeability of the membrane [35]. A stock solution of 10 mg/mL was prepared 
by dissolving the cholesterol in chloroform: methanol (2:1; v/v) and stores at -20 °C till the further 
use. 
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Figure 10. Chemical structure of Cholesterol 
2.1.6 Polymers 
2.1.6.1 PLGA  
PLGA (Resomer® RG 503 H; Poly(D,L-lactide-co-glycolide) 50:50) are the most widely used 
polyester-based synthetic biodegradable co-polymers, currently considered best biomaterial by 
the United States Food and Drug Administration (FDA) for the drug delivery due to their excellent 
biocompatibility, biodegradability, mechanical strength and controlled released properties. PLGA 
is synthesized via the ring-opening polymerization of two different monomeric units namely 
polylactic acid (PLA) and polyglycolic acid (PGA). During this process, these successive 
monomeric units are linked together by ester linkages, resulting linear aliphatic polyester 
products. The degradation products (i.e. lactic acid and glycolic acid) are readily eliminated from 
the body through body’s citric acid cycle and do not require the surgical procedures from their 
removal from the body [36, 37]. The release from the drug-loaded PLGA nano or microparticles 
can be controlled by varying its monomeric ratio (lactide: glycolide). It is estimated that time 
required for the hydrolytic degradation of PLGA is dependent on different factors including (1) 
co-polymer ratio, (2) end group (ester or free carboxyl group), (3) molecular weight, (4) glass 
transition temperature (5) viscosity of the polymer, (6) solubility of the drug, (7) pH of the 
biodegradation media, (8) temperature, (9) drug loading, and (10) porosity. In General, presence 
of the higher glycolide contents, low molecular weight, amorphous nature, presence of free 
carboxylic end group and smaller nanoparticle size leads to the faster degradation and drug release 
[38, 39]. In our study, acid terminated PLGA (Resomer® RG 503 H) with lactide to glycolide ratio 
in 50:50 and a molecular weight of 24,000-38,000 g/mol was used for the preparation of PLGA 
nanoparticles. Resomer 503 H has the fastest degradation time of less than 3 months as compared 
to all other PLGA grades with a viscosity of 0.32- 0.44 g/dL and a transition temperature (Tg) of 
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44- 48 ºC. A stock solution of 20 mg/mL of the polymer was prepared in the ethyl acetate, filtered 
using a 0.2 µm Nylon syringe filter and stored at -20 ºC until further use. 
 
Figure 11. Chemical structure of PLGA; Resomer RG 503H. Where ‘x’ and ‘y’ represents the 
successive monomeric units of lactic acid and glycolic acids respectively 
2.1.6.2 Chitosan  
Chitosan ((14),2-amino-2-deoxy-ß-D-glucan) is semi-synthetic polysaccharide obtained from 
the deacetylation of the naturally occurring polymer chitin. Chitin is one of the most abundant 
polysaccharides in nature and is the major constituent of the exoskeleton of the arthropods such 
as crabs, shrimps, lobsters, and insects. Several billion tons of the chitin is produced every year 
by the marine copepods alone. Chitosan molecule is a copolymer in which N-acetylglucosamine 
(2-acetylamino-2-deoxy-D-glucopyranose) and glucosamine units are linked together through 
14 glucosidic bonds. where the glucosamine content is more than 90%. Chitosan is relatively 
insoluble in water but soluble in acid. Chitosan has been used in variety of biochemical 
applications such as hemodialysis membrane, tissue engineering, artificial skin, wound healing, 
and drug delivery systems. It also shows antibacterial (bacteriostatic, bactericidal) and anti-yeast 
(candidacidal) properties in vitro [40, 41].  Being a biodegradable and biocompatible biomolecule, 
it has used in the regenerating blood/ tissue interface. It has a similar structural property of that of 
glucosamine-glycans and seems to mimic their functional behaviour. It can be degraded into the 
by the lysozymes into N-acetyl glucosamine, which can be used in the synthesis of glycoproteins 
or can be excreted out as carbon dioxide after further degradation [42].  In the recent study, 
ultrapure chitosan from shrimp shells with a molecular weight of 150 KDa and viscosity (η) of ≤ 
200 mPa.s was used.  
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Figure 12. Chemical structure of Chitin and Chitosan [43] 
2.1.6.4 PVA 
Polyvinyl alcohols (PVA) are the synthetic polymers used in a large number of commercial, food, 
industrial and biomedical applications. Based on the method of preparation, it is divided into two 
categories, fully hydrolyzed and partially hydrolyzed. Its physical characteristics depend on the 
method of preparation from the hydrolysis of polyvinyl acetate (PVAc). PVA is found to have 
very low or no acute toxicity and mutagenic or clastogenic potential. It is poorly absorbed from 
the gastrointestinal tract and does not accumulate in the body [44, 45]. Based on all these 
properties, PVA is most commonly used emulsifier in the drug delivery systems e.g. polymeric 
nanoparticles, nanofibers, and orodispersible membranes, etc. In our study Mowiol 4-88 with a 
molecular weight of Mw ~31,000 with a viscosity of 3.5-4.5 mPa (4% in H2O at 20 ºC) was used 
as a surfactant for the preparation of PLGA nanoparticles. It exists in the form of colourless to 
light yellow granules and is partly hydrolyzed with high adhesive power. A stock solution of 5% 
w/v was prepared in distilled water and stored at 4 ºC until further use.   
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Figure 13. Chemical structure of A) partly hydrolyzed and B) fully hydrolyzed PVA 
2.1.7 Drugs 
2.1.7.1 Temoporfin 
mTHPC (5, 10, 15, 20-Tetrakis (3- hydroxyphenyl) chlorine; Temoporfin) is one of the oldest yet 
most potent 2nd generation synthetic photosensitizers (PS) belonging to the family of chlorine 
photosensitizers. mTHPC is a non-polar compound with a molecular weight of 680.8 g/mol and 
is derived from the reduction of mTHPP (meso-tetra-hydroxyphenyl-porphyrin). mTHPC requires 
lower activation energies to produce an efficient photodynamic effect. Being a chlorine 
compound, it is activated with the red light at a longer wavelength of 650-652 nm and is indicated 
for the treatment of the different types of cancers i.e. head and neck carcinoma. Beside the clinical 
results, mTHPC is estimated to be 100-200 times more potent than Photofrin®. However, the 
hydrophobic mTHPC molecules tend to form aggregates in the aqueous media and bind strongly 
to serum proteins, leading to the limitation in its transportation within the biological media, tumor 
selectivity, limited bioavailability and hence in photodynamic therapy (PDT) [46, 47]. In the 
present study, mTHPC was encapsulated in different liposomal formulations in an attempt to 
increase its bioavailability, high tumor selectivity and to reduce the potential side effect (e.g. dark 
toxicity). A stock solution of 1 mg/mL was prepared by dissolving the pure drug (≥95%) in 
ethanol and stored at -20 °C until further use. 
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Figure 14. Chemical structure of Temoporfin (mTHPC) 
2.1.7.2 Pirarubicin  
Pirarubicin (2′′ R)-4′-O-tetrahydropranyl doxorubicin; THP) is an anthracycline derivative that 
inhibits type II topoisomerase and DNA polymerase. THP has a molecular weight of 627.64 
g/mol. It is a pyranyl derivative of doxorubicin and involve the generation of reactive oxygen 
spices (ROS). Due to the presence of the pyranyl group and its lipophilic properties, it exhibits a 
more potent anticancer activity and faster cellular uptake than doxorubicin [48]. It is used for the 
treatment of a variety of cancer such as head, neck, breast, and lymphoma. The limitation of the 
pirarubicin mediated chemotherapy is the indiscriminate distribution into normal the body tissues 
and organs before its delivery to the tumor thus causing adverse effects such as bone marrow 
suppression and cardiac and renal toxicity. All these adverse effects limit the use of THP in 
clinical settings [49]. The pharmacokinetic parameters of THP can be modified by encapsulating 
it into a nanoparticulate system thus reducing the side effects and increasing the efficacy of the 
system. Nanocarriers composed of PLGA have been investigated to carry the drugs to their 
designated site of action. Being biocompatible and biodegradable in nature, PLGA nanoparticles 
are interesting vehicles for the systemic delivery of THP. A stock solution of 1 mg/mL was 
prepared by dissolving the THP in ethyl acetate and stores at -20 °C till the further use 
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Figure 15. Chemical structure of Pirarubicin (THP) 
2.2 Methods 
2.2.1 Preparation of mTHPC loaded liposomes 
Liposomes were formulated using the traditional thin-film hydration method [50]. Briefly, five 
different lipid compositions; DPPC/Cholesterol (90:10 molar ratio), DPPC/DPPE-mPEG5000 
(95:5 molar ratio), DPPC/TEL (90:10 molar ratio), DPPC/DOTAP (90:10) and DPPC/DPPG 
(90:10) were dissolved in organic solvent mixture (chloroform: methanol 2:1; v/v). The organic 
solvents were evaporated using a rotary evaporator (Heidolph Laborota 4000 efficient, Heidolph 
Instruments, Schwabach, Germany) equipped with a vacuum pump at 41°C. For drug-loaded 
liposomes, mTHPC was added to the lipid mixture in a ratio of 1:20. The film was then re-
hydrated using 1 mL of PBS (pH 7.4) and thoroughly agitated to form 7.35×10-3 M mTHPC loaded 
liposomes. The pre-formed liposomes were then sonicated in a bath-type sonicator (Elmasonic P, 
Elma Schmidbauer, Singen, Germany) above the phase transition temperature (Tg) of the 
dominant lipid (i.e. DPPC=41◦C) for 15 min. The obtained multilamellar liposomes (MLVs) were 
then extruded 21 times using polycarbonate membrane filters (Nuclepore track-etch membrane, 
Whatman GmbH, Germany) first through 200 nm and subsequently from 100 nm using Avanti 
mini-extruder® (Avanti Polar Lipids, Alabama, USA) to obtain unilamellar liposomes. The 
extruded liposomes were stored at 4°C until further analysis [51]. 
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Figure 16. Schematic representation of photodynamic therapy (PDT) using mTHPC loaded 
tetraether (TEL) based liposomes illustrating the cellular photodynamic therapy, morphological 
characterization using atomic force microscopy and in-ovo photo-thrombic activity 
2.2.2 Preparation of Pirarubicin loaded nanoparticles 
THP loaded PLGA nanoparticles and unloaded (blank) nanoparticles were prepared using the 
emulsion solvent evaporation technique as described by Kumar et al [52]. Briefly, the THP stock 
solution was prepared by dissolving THP in ethyl acetate at a concentration of 1 mg/mL. 100 mg 
of PLGA was dissolved in 5 mL of ethyl acetate containing 2mg THP. The polymer-drug solution 
(organic phase) was then passed through a 0.2 µm Nylon syringe filter (Pall Corporation, New 
York, USA) and was then added dropwise into the 0.3% or 1% (w/v) PVA solution (aqueous 
phase). The formed o/w emulsion was then homogenized at 15000 rpm using Ultra-turrax with 
18G stainless steel dispersing head (IKA-Werke, Staufen, Germany) for 10 min. 1 mL of chitosan 
(0.1% w/v chitosan) was added to the formed nano-emulsion. The nanoprecipitation was 
amplified by the addition of ultrapure water dropwise to make up the volume to 30 mL. The 
organic phase was allowed to evaporate overnight by continuous stirring at room temperature to 
form the nanoparticle suspension. The same procedure was followed to prepare the blank 
nanoparticles except for the addition of the THP stock solution. The following day, after the 
complete evaporation of the organic solvent, the nanoparticle suspension was centrifuged at 2000x 
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g for 45 s using Eppendorf centrifuge 4518 (Eppendorf, Hamburg, Germany) to remove any 
formed agglomerates. The resultant pellet was discarded and the supernatant was washed with 
water to separate the unentrapped drug from the nanoparticles. The washing of the nanoparticles 
was done twice at 16000x g for 20min. The nanoparticles suspension was then freeze-dried using 
an Alpha 1-4LSC lyophilizer (Martin Christ Gefriertrocknungsanlagen, Osterode am Harz, 
Germany) using 0.2% PVA as a cryoprotectant. The lyophilized nanoparticles were stored at 2-8 
ºC until further analysis [53]. 
 
Figure 17. Schematic representation of THP loaded PLGA nanoparticles using emulsion solvent 
evaporation technique 
2.2.3. Preparation of lipid enveloped nanoparticles:  
The stoichiometry describes the relationship (typically a ratio) between the relative quantities of 
the substances taking part in a particular reaction or forming a compound. To optimize the 
stoichiometry of mTHPC loaded liposomes and THP loaded PLGA nanoparticles different 
Liposome: NP ratios were attempted and were then optimized to 1: 100. Consequently, to coat 
pre-formed liposomes over the pre-formed nanoparticles, an appropriate amount of mTHPC 
loaded liposomes was added to the THP loaded PLGA nanoparticle suspension and mixed 
thoroughly. The mixture was incubated and then sonicated for 20min, resulting in a self-organized 
lipid bilayer on the nanoparticle’s surface [54, 55]. 
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Figure 18. Schematic illustration of the preparation of lipid coated PLGA nanoparticles 
2.2.4 Physicochemical characterizations 
2.2.4.1 Photon correlation spectroscopy 
The hydrodynamic diameter of the liposomes was measured by PCS using Nano ZS Zetasizer 
(Malvern Panalytical GmbH, Kassel, Germany), equipped with a 10 mW HeNe laser at a 
wavelength of 633 nm at 25°C and scattered light detection at 173°. Laser attenuation and 
measurement positions were automatically adjusted by the instrument with each measurement. 
The average particle diameter and polydispersity index (PDI) was always measured using 
disposable capillary cell (DTS1060, Malvern Instruments) for all the samples by diluting the 
liposomes (1:100) with purified water [56]. Data are expressed as mean ± standard deviation (SD) 
from the measurement of three independent samples (n=3) with each measurement comprising of 
15 individual runs. All the results were expressed as the size distribution by intensity. 
2.2.4.2 Laser doppler anemometry 
The Zeta potential (ζ) of mTHPC loaded liposomes was performed with Nano ZS Zetasizer by 
measuring the electrophoretic mobility with LDV at 25°C and a scattering angle collection at 17°. 
A clear disposable folded capillary cell (DTS1060) was used for this purpose. Prior to 
measurement, the samples were subsequently diluted as described above. The values are 
expressed as mean ± SD for the measurement of three independent samples. Three individual 
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samples were measured for this purpose with every measurement having 15 - 100 runs, depending 
on the sample [57].  
2.2.4.3 Encapsulation efficiency 
2.2.4.3.1 Encapsulation efficiency of mTHPC loaded liposomes 
The encapsulation efficiency (EE%) of mTHPC loaded liposomes was determined by the solvent 
extraction technique using air-driven ultracentrifuge Airfuge® (Beckman Coulter GmbH, Krefeld, 
Germany). Briefly, 200 µl of prepared liposomes were centrifuged for 90 min at 20 PSIG (60,000 
rpm) using Beckman Polyallomer microcentrifuge tubes (Beckman Coulter GmbH, Krefeld, 
Germany). After centrifugation, the supernatant was separated and the pellet was resuspended 
using 200 µl of ethanol. Similarly, an equal amount of ethanol was added to the supernatant. 
Further centrifugation steps were carried out to remove and discard any undissolved lipids. The 
amount of mTHPC encapsulated was quantified from both solutions using Multiskan™ GO 
UV/VIS microplate spectrophotometer (Thermo Fischer Scientific GmbH, Dreieich, Germany). 
Liposomes having the same lipid composition without mTHPC were used as a blank. The 
calibration curve for mTHPC was constructed in both ethanol and ethanol/water (1:1) [58]. 
2.2.4.3.2 Encapsulation efficiency of THP loaded PLGA nanoparticles 
The encapsulation efficiency from the THP loaded PLGA nanoparticles was determined also by 
the solvent extracting technique. Briefly, 1 mL of freshly prepared nanoparticle suspension was 
centrifuged at 16000x g for 20min using Eppendorf centrifuge 4518 (Eppendorf, Hamburg, 
Germany) to separate the unentrapped drug. The supernatant was withdrawn and an equal volume 
of acetonitrile was added to the supernatant. Similarly, the nanoparticle pellet was dissolved by 
the addition of 1 mL acetonitrile and sonicated for 15 min for the complete extraction of the drug. 
The absorbance from both of the solutions was determined using a UV/VIS spectrophotometer 
(UV mini 1240, Shimadzu, Japan) at 230 nm. Nanoparticles without drug were taken as blank 
control. The amount of drug encapsulated was quantified using the calibration curves constructed 
in the same solvent systems with known THP concentrations [53].  
The EE% was determined using the following formula: 
EE% =
Amount of drug encapsulated 
Total amount of drug added
× 100 . . . . . 𝐄𝐪. [𝟏]  
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2.2.4.4 In vitro drug release profile: 
The release profile of pirarubicin loaded nanoparticles was carried out in PBS (pH 7.4) containing 
1% tween 80 (v/v). Briefly, the freshly prepared nanoparticles were washed as described earlier. 
The nanoparticle pellet containing 0.5 mg of the drug was then resuspended in 5 mL of PBS (pH 
7.4) with 1% tween 80 and placed in a shaking incubator (KS 4000 IC, IKA Werke, Staufen, 
Germany) at 100 rpm and 37 ºC. For the following days, 0.5 mL of the sample was withdrawn at 
specified time intervals. The sample was centrifuged at 15000x g for 10 min and the supernatant 
was separated. In order to assure the sink conditions, the pellet was resuspended in fresh PBS (pH 
7.4) containing 1 % tween 80 and returned to the original nanoparticle suspension. The amount 
of THP in the supernatant was analyzed spectrophotometrically using US/VIS spectrophotometer 
(UV mini 1240, Shimadzu, Japan) at 230 nm. At the end of the experiment, the nanoparticle pellet 
was dissolved in the acetonitrile and the amount of drug remained in the nanoparticles was also 
determined. For all the measurements, a background subtraction with blank PLGA nanoparticles 
(without drug) processed in the same way was carried out [57].  
2.2.5 Morphological characterizations 
2.2.5.1 Atomic force microscopy (AFM) 
A total of 50 µl of diluted sample dispersion (1:100 with purified water) was transferred to the 
silicon chip mounted on the glass slide and left to settle down for 15 min. The supernatant was 
then removed by aspiration using a lint-free tissue (KIMTECH Science, Kimberly-Clark Europe 
Limited) and the sample was allowed to dry. AFM was performed using vibration damped (i4 
Series - Active Vibration Isolation, Accurion GmbH, Göttingen, Germany) NanoWizard®-3 
NanoScience AFM system (JPK BioAFM, Bruker Nano GmbH, Berlin, Germany). Commercially 
available soft n-type silicon 1-lever cantilever tips HQ: NSC14/AL_BS (Mikromasch Europe, 
Wetzlar, Germany) with a resonance frequency of 160 KHz and nominal force constant of 5 N/m 
were used for the for the liposomes while HQ: NSC16/AL_BS (Mikromasch Europe, Wetzlar, 
Germany) cantilever tips with a resonance frequency of 190 KHz and force constant of 45 N/m 
were used for the measurement of THP loaded PLGA nanoparticles and lipid-coated 
nanoparticles. The scan speed was adjusted between 0.5-1.5 Hz. These measurements were 
performed using the intermittent contact mode in the air to avoid the sample disruption. The 
images were visualized using height measured, lock in-phase and lock in amplitude mode. The 
raw images were processed with JPK data processing software [59, 60]. 
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2.2.5.2 Transmission electron microscopy (TEM) 
For the transmission electron analysis (TEM) analysis, the samples were diluted to 1:50 with 
water. 15 μl of the diluted formulation was mounted on the 300 mesh formvar coated carbon 
supported 0.037 mm copper grids (Plano GmbH, Wetzlar, Germany). The sample was allowed to 
stand for 5 min. The supernatant was then removed and the samples were then negatively stained 
by adding 15 μl of 2% uranyl acetate on the copper grid (for contrast under the microscope) and 
allowed to incubate for 2min. After the incubation is over, the excess of uranyl acetate was 
removed using wet tissue. The samples were then analyzed under the JEM-1400 Transmission 
Electron Microscope (Jeol Ltd; Tokyo, Japan). The TEM was equipped with a high-resolution 
retractable CCD camera (Gatan Inc., Pleasanton, USA) and was operated at an accelerating 
voltage of 120KV with a beam current of 75 μA [61].  
2.2.5.3 Cryo-transmission electron microscopy (Cryo-TEM) 
Cryo-TEM was performed as described by Janich et al [62]. The vitrified liposomal samples were 
examined using the blotting technique. The process was performed at room temperature in a 
humidity-controlled environmental chamber of an EM GP grid plunger (Leica Microsystems, 
Wetzlar, Germany). Briefly, 6µl of the sample was placed on a grid coated with an ultra-flat holey 
carbon film (C-flat, Protochips Inc., Raleigh, NC). The excess liquid was removed by blotting 
using a filter paper. The grids were plunge-frozen immediately by immersing in liquid ethane and 
maintained at a temperature below 108 K (-165.15 °C). The frozen grids were transferred into a 
Libra 120 transmission electron microscope (Carl Zeiss Microscopy GmbH, Jena, Germany; 
acceleration voltage 120 kV) equipped with a Gatan 626 cryotransfer system. Images were taken 
with a BM-2k-120 dual-speed on-axis SSCCD camera (TRS, Moorenweis, Germany). 
2.2.6 In vitro cell culture experiments 
2.2.6.1 Cell line and culturing 
A wild-type human ovarian adenocarcinoma (SK-OV-3) cell line was procured from ATCC 
(American type culture collection, Manassas, USA). The cells were cultivated at 37°C and 7% 
CO2 under humid conditions in a high glucose DMDM supplemented with 10% FCS and MEM-
non-essential amino-acids (Gibco™, Thermo-Fischer). The cells were grown as a monolayer and 
passaged to confluency [50, 58]. 
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2.2.6.2 Light delivery to the cells 
A prototype LED device containing light-emitting diodes (Generation-I LED irradiator, 
Lumundus GmbH, Eisenach, Germany) was used. The device was equipped with the function to 
change the irradiation time (s) and current (mA) as required. It was supplied with two different 
LEDs of 457 nm (blue) and 652 nm (red) wavelengths. The device was able to deliver irradiance 
of 22.4 Wm-2 at a current of 20 mA and wavelength of 652 nm. Similarly, 220.2 W/m2 irradiance 
can be delivered at a current of 100 mA and a wavelength of 457 nm. The actual light dose (Jcm-
2) delivered to the cells seeded in 96 well plates is equal to irradiance (Wcm-2) times the irradiation 
time.  
2.2.6.3 Cytotoxicity studies 
2.2.6.3.1 MTT assay 
The cells were seeded in the clear flat bottom 96 well microtiter plates (Nunclon Delta, Thermo 
Fischer Scientific GmbH, Dreieich, Germany) at a seeding density of 10,000 cells/well (0.35cm2) 
and allowed to adhere overnight. Post 24 h stabilization, the cells were incubated with 100 µL/well 
of THP loaded nanoparticles and free THP (dissolved in DMSO) in different concentrations 
ranging from 100 µM to 0.78 µM (appropriately diluted with the medium) and were incubated for 
4 h. Post incubation, the samples were removed and fresh medium was added to the cells. The 
plates were then returned to the incubator and incubated overnight. After 24 h, the medium was 
replaced with the 200 µL of MTT appropriately diluted with medium (2 mg/mL) and incubated 
for 4 h. After the incubation, MTT dye was aspirated and formazan crystals were dissolved using 
200 µL of DMSO. The plates were incubated on a shaking incubator (IKA KS4000 IC, Staufen, 
Germany) for 20 min. The absorbance was recorded at 570 nm using FLUOStar Optima plate 
reader (BMG Labtech, Ortenberg, Germany). The cell viability of the untreated cells was 
considered to be 100%. The cell viability was determined using the formula [63]:  
Cell Viability % =
AbSample − AbBlank
AbControl − AbBlank
× 100 . . . . . 𝐄𝐪. [𝟐] 
where AbSample and AbControl denote the treated and untreated samples respectively. While AbBlank 
indicates the well containing medium without any cells. The values are expressed as mean ± SD 
with all the experiments performed in triplicate.  
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2.2.6.3.2 In vitro irradiation and cytotoxicity synergism 
The cellular photodynamic therapy (cPDT) for the mTHPC loaded liposomes and lipid-coated 
nanoparticles was performed using MTT assay as described above. For in vitro irradiation 
experiments, different concentrations of mTHPC loaded liposomes ranging from 5 µM to 0.05 
µM (appropriately diluted with the medium) were used. The incubation time was optimized for 2 
h after initial incubation for different times e.g. 1 h, 2 h, and 4 h. Post incubation, the liposomal 
formulations were replaced with fresh medium and the mTHPC taken up by the cells was 
irradiated at 652 nm (red) for 23, 223 and 446 S at a fluence of 22.4 Wm-2 (20 mA). This 
corresponds to 0.05, 0.5 and 1 Jcm-2 of the total light dose delivered respectively. Similarly, in 
other experiments, mTHPC was illuminated at 457 nm (blue) for 45, 227 and 455 sec at a fluence 
of 220.2 W/m2 (100 mA) which corresponds to 1, 5 and 10 Jcm-2 of total light energy delivered. 
An unirradiated well plate treated similarly with liposomal formulations was considered as dark 
control. Free mTHPC dissolved in DMSO was taken as a standard control whereas cells without 
any liposomal formulation were considered as a negative control [50]. 
Based on the results obtained from the physicochemical characterizations and the cell viability 
assay, THP nanoparticles with an average hydrodynamic diameter of 200 nm were considered to 
be the optimal size for the further studies. Consequently, these nanoparticles were coated with 
mTHPC loaded DPP/DPPG/mPEG5000-DPPE liposomes. The cell viability assay was also 
performed for the lipid-coated THP nanoparticles for the combined delivery of the mTHPC and 
THP to the cancer cells. For this purpose, the SK-OV-3 cells were incubated with similar 
concentrations of mTHPC loaded DPPC/DPPG/mPEG5000-DPPE liposomes as well as lipid-
coated THP nanoparticles (as described above) for 4 h. Post incubation, the medium was replaced 
and the cells were irradiated with different light fluences (i.e. 50 mJ/cm2 and 350 mJ/cm2) at a 
wavelength of 652 nm [64]. The next day, cell viability was determined using MTT assay.  
2.2.6.4 Measurement of cellular reactive oxygen species (cROS) 
The quantitative determination of ROS was performed using a free radical sensor and cell-
permeable fluorescent dye DCFDA. The assay was performed according to the DCFDA cellular 
ROS detection protocol from Abcam with slight modifications. Briefly, SK-OV-3 cells were 
seeded in the dark, clear bottom 96 well microtiter plates at a density of 25,000 cells/well. Cells 
were allowed to adhere overnight. On the following day, the cells were washed with PBS (pH 7.4) 
supplemented with Ca2+ and Mg2+ and were then incubated with 25 µM of DCFDA, by incubation 
for 45 min at 37 ºC. After washing again with PBS, they were incubated with liposomes for 2 h. 
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50 µM of TBHP was used as a positive control. After the incubation, cells were irradiated at a 
radiation fluence of 1 Jcm-2 at 457 and 652 nm. The cells were then washed with PBS and the 
fluorescence was recorded at λex 480 nm/λem 520 nm using FLUOStar Optima plate reader. Based 
on the results obtained from cPDT and measurement of cROS, the irradiation was done using 
652 nm wavelength light for the further experiments [65]. 
2.2.6.5 Intracellular uptake studies 
For intracellular uptake analysis of mTHPC encapsulated liposomes, SK-OV-3 cells were seeded 
onto the sterile cover glasses (15 x 15 mm) placed in 12 well cell culture plates (Nunclon Delta, 
Nunc GmbH & Co. KG., Wiesbaden, Germany) at a density of 90,000 cells/well. After 24 h, the 
medium was replaced by 5 µM of mTHPC loaded liposomes and incubated for 2 h at 37°C. After 
the incubation, the medium was aspirated and cells were washed twice with sterile ice-cold PBS 
(pH 7.4) supplemented with Ca2+ & Mg2+. The cells were then fixed with 4% formaldehyde by 
incubating the cells for 20 min at room temperature. They were then washed again with PBS 
(pH 7.4). The cell nuclei were counterstained with 50nM of Sytox green™ nucleic acid stain 
(Thermo-Fischer Scientific GmbH, Dreieich, Germany) for 20 min. After washing twice with 
PBS (pH 7.4), the cover glasses were then removed from the well plate, mounted on glass slides 
and sealed with fluorescence free glycerol-based FluorSave™ reagent (Calbiochem, San Diego, 
USA). The stained cells were then observed under the LSM700 confocal laser-scanning 
microscope (Carl Zeiss Microscopy, Jena, Germany). The cellular uptake was then observed using 
fluorescence detection filters for Sytox green™ (λex/em 504⁄523 nm) and mTHPC (λex/em 420/652 
nm) [65, 66]. 
2.2.6.6 In vitro genotoxicity assessment  
The single-cell gel electrophoresis (Alkaline comet assay) was used to assess the DNA damage 
and genotoxicity induced by mTHPC encapsulated liposomes. All the procedures were performed 
in dark [67]. Briefly, 1,00,000 SK-OV-3 cells per well were seeded into a six-well plate and were 
allowed to adhere overnight. The following day the cells were incubated with 0.5 µM of mTHPC 
loaded liposomes, 20 µM of THP loaded nanoparticles and similar concentrations of lipid-coated 
PLGA nanoparticles for 4 h. After the incubation is over, the mTHPC liposomes were replaced 
with the fresh medium. Consequently, the cells were irradiated at an equitoxic light dose to 
produce 80% cell viability in order to avoid any false positive responses. The treated cells were 
then incubated overnight. The next day, the cells were trypsinized and centrifuged for 5 min at 
1000 rpm to get the cell pellet. The obtained cell suspension was washed twice using sterile PBS 
38 
 
(pH 7.4) and cell density was adjusted accordingly. As a next step, 80,000 cells (25 µl) of the PDT 
treated cell suspension was mixed with 75 µl of 1% of prewarm low melting agarose (LMA) (Carl 
Roth GmbH, Karlsruhe, Germany). The mixture was applied on the superfrost glass slide 
previously precoated with of 1% standard normal melting agarose (NMA) and was immediately 
covered with coverslips. The glass slides were then placed on an ice block for 10 min until 
solidified and the coverslips were gently removed. The cell membrane lysis was done by 
submerging the slides overnight into the staining jar containing cold lysis solution (300 mM 
NaOH, 1.2 M NaCl, 2% DMSO and 1% Triton™ X-100). The slides were then transferred to the 
electrophoresis tank containing alkaline electrophoresis buffer (300 mM NaOH and 1mM EDTA) 
and were left in the buffer for 30min to allow the unwinding of DNA. Electrophoresis was 
performed for 30 min at 250 mA current and 25 V, resulting in the DNA unwinding and exposing 
the alkali labile sites. After the electrophoresis, the slides were neutralized by washing the slides 
with double distilled water. The cell fixation was then done by submerging the slides into the 70% 
ethanol for 20 min. After fixation, the slides were cells were stained with SYBR® safe DNA 
staining dye (1:10000 in PBS) for 20 min [68]. Finally, the slides were washed with double 
distilled water to remove any unbound stains. The comet analysis was done under a fluorescence 
microscope (CKX-53 Olympus, USA). Fifty individual comets were scored for each formulation.  
2.2.6.7 Cellular uptake pathway analysis 
In order to determine the liposomal uptake mechanism by the cells, the SK-OV-3 cells were 
seeded into a 96 well plate at a seeding density of 10,000 cells/well and were allowed to adhere 
overnight by maintaining at 37°C and 5% CO2. The next day, the cells were washed with PBS 
(pH 7.4) supplemented with Ca2+/Mg2+. The cells were then pre-incubated with the inhibitors of 
the vesicular uptake pathway (i.e. Chlorpromazine 30 µM and Filipin-III 15 µM) for 1 h. After 
incubation is over, the nanoformulations (mTHPC-LP, THP-NP, LCNP as well as free drugs) 
were added to the cells and were again incubated for a total of 4 h. Post incubation, the samples 
were replaced by fresh medium and irradiation was performed at a light dose of 0.5 Jcm-2. 
Subsequently, the cells were incubated again for 24 h. Un-irradiated plates were taken as the dark 
control. The following day, cell viability was determined using MTT assay as described 
previously [51]. 
2.2.6.8 Apoptosis assay using flow cytometry  
The cell apoptosis assay was performed using flow cytometry APC annexin V (human vascular 
anticoagulant) according to the manufacturer protocol with slight modifications. Briefly, 90,000 
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SK-OV-3 cells per well were seeded in 12-well cell culture plates and were allowed to adhere 
overnight. Post stabilization, the cells were incubated with the nanoformulations at a 
concentration of 1.5µM of mTHPC loaded liposomes, 15µM of THP loaded nanoparticles and 
similar concentrations of the lipid-coated nanoparticles containing mTHPC and THP to get 60% 
cell viability. The cells were then incubated for 4 h. Post incubation, the formulations were 
replaced with the fresh medium. The cells were then irradiated with a light dose of 0.05 Jcm-2 at 
652 nm (except for THP loaded nanoparticles and free THP). The cells without any treatment 
were taken as the negative control. The plates were then returned to the incubator for overnight. 
The following day, cells were trypsinized, washed with ice-cold PBS (pH 7.4) without Ca2+/Mg2+ 
and resuspended in 1X binding buffer. 50µL of binding buffer supplemented with 1µL (10 µg/ 
ml) of APC annexin V were gently mixed with an equal volume of the cell suspension and 
incubated at room temperature for 15 min under dark conditions. After the incubation is over, a 
300 µL of binding buffer containing 0.4 µL (5 mg/mL) of propidium iodide (PI) was added and 
placed in ice for 5 min. The apoptosis analysis was then conducted by flow cytometry (Guava® 
easyCyteTM, Millipore Sigma, USA). The data was processed by FlowJo® v. 10.6 software. 
2.2.6.9 Biocompatibility studies 
2.2.6.9.1 Ex-vivo hemolysis assay 
To evaluate the effect of mTHPC loaded liposomes on human blood, the ex-vivo hemolysis assay 
was performed as described by Raschpichler et al [69].  Briefly, 10 mL of fresh human blood was 
drawn into the EDTA tubes to prevent the coagulation and centrifuged at 500 × g for 5 min, 
resulting in separation of blood plasma from the human erythrocytes. The plasma was aspirated 
and erythrocyte pellet was washed three times with sterile PBS (pH 7.4) and diluted to 1:50 with 
PBS. mTHPC loaded liposomes (10X of the desired final concentration tested in cell culture 
experiments) were then incubated with erythrocytes in V-bottom microtiter plates for 1 h at 37°C 
in an orbital shaker KS4000 IC (IKA Werke, Staufen, Germany). The plates were then centrifuged 
and the supernatant was transferred into a clear flat bottom 96 well plate. The absorbance was 
measured at 540 nm using FLUOStar Optima plate reader. Sterile filtered PBS (pH 7.4) and 1% 
Triton™ X-100 were taken as negative and positive controls, respectively. The absorbance value 
from Triton™ X-100 was considered as 100% hemolysis. The assay was done in triplicate and the 
results were expressed as mean ±SD. The percentage of hemolysis was calculated using the 
formula [69]: 
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𝐇𝐞𝐦𝐨𝐥𝐲𝐬𝐢𝐬 [%] =
AbSample − AbNc
AbPC − AbNc
 X 100 . . . . . 𝐄𝐪 [𝟑] 
2.2.6.9.2 Activated partial thromboplastin time test (aPTT) 
In order to verify that the mTHPC loaded liposomes do not trigger the coagulation cascade upon 
intravenous administration, aPTT test was performed as described by Pinnapireddy et al [70]. The 
test was performed in the Coatron M1 coagulation analyzer (TECO GmbH, Neufahrn, Germany) 
using TEClot aPTT-S kit as described by the manufacturer’s manual with slight modifications.  
Briefly, fresh blood was drawn in a citrate tube and centrifuged at 1500 × g for 15min to separate 
the blood plasma. 25 µl of the plasma was mixed with 25 µl of the sample, followed by the 
addition of 50 µl of aPTT reagent for the activation of coagulation factors. Finally, 0.025 M 
prewarm calcium chloride (CaCl2) was added to the mixture to activate the coagulation of blood. 
Coagulation was confirmed spectrophotometrically, and the clotting time was recorded in 
seconds. The experiments were performed in triplicate and the results were expressed as mean 
±SD [70]. 
2.2.6.9.3 Photo-thrombic activity of mTHPC liposomes (CAM assay) 
Fertilized eggs weighing 50-60 g were purchased from Mastkükenbrüterei Brormann (Rheda-
Wiedenbruck, Germany). After the delivery, the eggs were disinfected with ethanol (70%) and 
placed in a hatching incubator (Dipl. Ing. W. Ehret GmbH, Emmendingen, Germany) equipped 
with the automatic rotator at a temperature of 37°C and relative humidity of 65%. The intact chick 
CAM angiogenesis model was used as described by Tariq et al [71], with slight modifications. 
Briefly, on egg development day 4 (EDD 4), a 30 mm hole was made on the apical part of the egg 
with the help of pneumatic Egg Puncher (Schuett Biotech GmbH, Germany) at a pressure of about 
2-3 bars to expose the premature CAM surface. The exposed surface was then covered with a 
small petri dish and placed back to the incubator in the static upright position until the CAM was 
fully developed. On EDD 12, 100 µl of the liposomal sample (200 µM) was injected intravenously 
in-ovo using a stereo-microscope (Stemi 2000-C, Carl Zeiss GmbH, Jena, Germany) and 
incubated for 60 min. After the homogenous distribution of the sample, a PVC ring (diameter 5 
mm) was placed on a predefined treatment area. An image of the CAM surface was recorded prior 
to irradiation. Subsequently, the chosen area was irradiated using a red laser diode (652 nm, 40 
mW) with Weber needle (Weber Medical GmbH, Lauenförde, Germany). The irradiation was 
performed for 2 min at an area of 3.1 mm2 that corresponds to 4.8 Jcm-2 energy (optimized energy; 
data not shown).  Vascular occlusion was recorded post-irradiation from 10 min to 48 h using 
41 
 
Stemi 2000-C stereo-microscope (Carl Zeiss GmbH, Jena, Germany) attached with a Moticam 5 
CMOS camera (Motic Deutschland GmbH, Wetzlar, Germany). For each liposomal formulation, 
the experiment was performed in triplicate and images were recorded pre and post photodynamic 
treatment. Eggs treated with normal saline were considered as a negative control [72, 73]. 
2.2.6.10 Serum stability studies: 
The stability studies of mTHPC encapsulated liposomes were conducted in simulated conditions. 
In order to simulate the physiological conditions, 0.2 mL mTHPC loaded liposomes were mixed 
with 1 mL of 60% FCS (diluted in PBS (pH 7.4) to get a volume ratio of 5. Similarly, 1 mL PBS 
(pH 7.4) was also mixed with 0.2 mL of mTHPC containing liposomes to get the same volume 
ratio of 5. Both of the mixtures were then incubated for 24 h in a shaking incubator at 100 rpm 
and 37ºC. In the control experiments, only PBS (pH 7.4) was mixed with FCS keeping the other 
parameters constant. The samples were withdrawn at specific time intervals, appropriately diluted 
with purified water and measured using Nano ZS Zetasizer. The results were obtained for, three 
independent formulations [74]. 
2.2.6.11 In vivo experiments 
2.2.6.11.1 Animals 
Healthy female albino (BALB/c) mice weighing 30-35 g with an age 8-10 weeks were obtained 
from the National Institute of Health, Islamabad. All the animals were provided free access to 
water and commercial laboratory food (ad libitum). They were housed in a controlled environment 
(Temperature: 22 ± 2 ºC, Humidity: 60 ± 10% with a 12 h light/ dark cycle). All the experiments 
were performed as per defined protocols approved by the Bio-ethical committee of Riphah 
Institute of Pharmaceutical Sciences, Riphah International University, Lahore, Pakistan. 
2.2.6.11.2 In vivo acute toxicity assessment 
In vivo, acute toxicity studies were determined in mice for 7 days as per the Organization for 
Economic Cooperation and Development (OECD) 425 guidelines [75]. Briefly, the animals were 
randomly assigned into 6 groups with each group comprising of 3 animals (n= 3). Group 1 and 
group 2 were administered with free mTHPC (dissolved in 0.1% DMSO) and mTHPC loaded 
liposomes respectively (mTHPC dose equivalent to 0.150 mg kg-1 body weight). Similarly, Group 
3 and group 4 were treated with free THP (dissolved in 0.1% DMSO) and THP loaded 
nanoparticles respectively (THP dose equivalent to 5 mg kg-1 body weight). Group 5 was treated 
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with lipid-coated nanoparticles and group 6 was treated with normal saline (considered as the 
control group). The formulations were administered in two equally divided doses (viz day 1 and 
3) intravenously via tail vein using a 21-gauge needle. The animals were kept under observation 
for 1-7 days for any sign of changes in the body weight, visual observations of mortality, 
behavioral patterns (e.g. skin and fur, eyes, salivation, respiration, consistency of feces, urine 
color, sleep patterns, convulsions and coma, etc.), any sign of illness throughout the study period. 
After 7 days of observations, the blood was withdrawn for blood biochemical analysis and the 
mice were euthanized for tissue histological studies [76, 77]. 
2.2.6.11.3 Blood biomarker assay 
In an attempt to determine the toxicity of our formulations on the mice's blood, serum biochemical 
indexes were analyzed. After 7 days post-exposure, blood from each mouse was withdrawn under 
anesthesia into a sterile tube via thoracic puncture. In order to separate the plasma, the blood was 
centrifuged at 1200x g for 10 min, using the centrifuge (Centurion Scientific, Chichester, UK). 
The supernatant was removed carefully and stored at -20 °C until further analysis. Serum 
biochemical markers including renal function tests (RFTs), liver function tests (LFTs) including, 
bilirubin level, creatinine level, blood urea, total protein, and cholesterol level were performed 
using serum biochemical marker analyzer (MicroLab 300, Merck, Germany).  
Hematological investigations were conducted on the heparinized part of the blood. Complete 
blood screening including total erythrocyte count (TEC), hemoglobin concentration (Hb), mean 
corpuscular volume (MCV), hematocrit (HCT), mean corpuscular hemoglobin (MCH), mean 
corpuscular hemoglobin concentration (MCHC), total leucocyte count (TLC), platelet count as 
well as mean platelet volume (MPV) were performed using a hematology analyzer (Icon-3, Norma 
Instruments, Budapest, Hungary) [78]. 
2.2.6.11.4 Body visceral index 
Body visceral index is a vital tool to evaluate any toxic effect of the nanoformulations on mice’s 
organs after their repeated administration. Change in body organ weight was determined at the 
end of the treatment (post 7 days). The animals were euthanized by cervical dislocation method 
and vital body organs (i.e. heart, kidney, liver, and lungs) were removed, washed carefully with 
sterile normal saline and weighed. The organ weights were then compared with the body organ 
weights of the control group to determine the organ body weight index using the formula [79, 80]:  
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𝐁𝐨𝐝𝐲 𝐕𝐢𝐬𝐜𝐞𝐫𝐚𝐥 𝐈𝐧𝐝𝐞𝐱 [%] =
Organ weight
Body weight
X 100 . . . . . 𝐄𝐪 [𝟒] 
2.2.6.11.5 Erythrocyte adhesiveness test (EAAT) 
The erythrocyte aggregation test is a simple test that indirectly reveals the presence and proportion 
of the inflammation. It is a commonly used screening test for high-risk individuals for myocardial 
infarction. For EAAT, the erythrocytes of the mice were separated from the other blood 
components and washed three times with sterile PBS by centrifugation at 5,000 g for 5 min. The 
RBC pellet was then re-suspended with PBS to make a final stock suspension of 2% (v/v). A 100 
μl of the erythrocyte suspension was mixed with 100 μl of the nanoformulations containing 50 
µM of mTHPC and 75 µM THP and were then incubated for 2 h at room temperature. After the 
incubation, 10 μl of the sample mixture was placed on a glass slide and observed under bright 
field microscopy [81]. 
2.2.6.11.6 Histopathological examinations  
In order to examine any pathological changes (i.e. abnormalities or lesions) induced by our 
formulations, histopathological examinations were done as described. Briefly, after sacrificing the 
animal, the vital organs were removed and washed carefully with normal saline. The organs were 
immediately placed in 10% formalin solution. The organs were then embedded into the paraffin 
blocks and sliced carefully into 0.5 µm thin tissue sections using a rotary microtome (Hunan Kaida 
Scientific Instruments, Changsha, China). The sections were then fixed onto the glass slides and 
stained with hematoxylin-eosin periodic acid Schiff (PAS) stain (H-E stain). The slides were 
examined microscopically and photos were taken using a microscope (Olympus BX51M, Tokyo, 
Japan) [80].  
2.3 Statistical analysis: 
Non-linear curve fitting functions were applied on normalized dose-response cell viability data 
obtained from the MTT assay and the IC50 values were calculated. All the experiments were 
performed in triplicate unless otherwise stated and results are expressed as mean ± SD. Two-way 
analysis of variance (ANOVA) with Dunnett’s test (multiple comparisons against a control group) 
was performed for the comparison of percentage viability obtained from cytotoxicity assays. One-
way ANOVA with post hoc test (Dunnett’s multiple comparisons against control) was performed 
on the rest of the data using Graph Pad Prism 5. Significance levels of p<0.05 were considered 
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for the rejection of the nulls hypothesis. Statistical significance is expressed as *p < 0.05, **p < 
0.01, ***p < 0.001 and ****p < 0.0001.  
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Chapter III: Results and Discussion 
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3.1 mTHPC (Temoporfin) loaded liposomes 
3.1.1 Physicochemical characterizations  
Liposomal formulations not only facilitate the administration of the hydrophobic PS but also avoid 
their precipitation into aggregated form and result in increased bioavailability with higher 
accumulation of PS at the tumor site [82]. By assimilating the PS into the liposome, the fluidity 
of the system can be altered and hence delivery process of the PS can be modified. mTHPC being 
a hydrophobic molecule, tend to align itself in the non-polar region of the liposomal bilayer 
membrane where it contributes to strong hydrogen-bonding interactions with the polar heads of 
the phospholipids (e.g. DPPC). mTHPC acts as a hydrogen donor because of the strong electron-
withdrawing effect of the aromatic ring of its phenolic constituents [83]. This drug-lipid 
interaction lowers the molecular motion of phospholipids giving rise to more rigid and stable 
systems. Physically these interactions are also responsible for higher loading capacity and reduced 
fluidity of the membrane [84, 85]. In the current study, five different liposomal formulations were 
used to study their effect on cellular uptake, serum stability, biocompatibility, and light-induced 
toxicity. The composition of prepared liposomes and their physicochemical properties are 
presented in Table 1. All the prepared liposomal formulations contained DPPC as major vesicle-
forming lipid combined with other lipids in specified molar fractions. No significant modification 
of liposomal size and zeta potential was induced owing to the presence of different DPPC molar 
ratios in different liposome formulations. The hydrodynamic diameter of all the formulations was 
in nanometric range, ranging from 106.0 ± 5.5 nm to 132.5 ± 8.6 nm with a PDI of less than 0.2 
for the formulation containing DPPC/Cholesterol and DPPC/DOTAP, which represents the 
narrow monomodal distribution of liposomal vesicles. The liposome containing TEL, DPPG and 
DPPE-mPEG5000 in small molar fractions exhibited a PDI of more than 0.2. This relatively 
higher PDI can be attributed to the presence of smaller rod and disc-shaped micellar structure as 
well as the large PEG chains present in a formulation that also gives a stealth effect to the liposome 
[25]. It is also attributed to the presence of some bi- or oligolamellar vesicles as confirmed 
morphological studies. All the liposomal formulation possessed an overall negative zeta potential 
ranging from -13.2 ± 2.0 to -6.6 ± 0.3 mV except for DOTAP containing liposome having a 
surface charge of 24.33 ± 12.2.  
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Table 1. Physicochemical properties of mTHPC loaded liposomes. Each liposome contains 0.5 
mg of mTHPC in 10 mg of total lipid. Hydrodynamic diameter is expressed as a function of 
particle size distribution by intensity. Values are expressed as mean ± SD for three independent 
measurements (n=3). 
Formulation (mol %) 
Diameter 
(nm) ± SD 
PDI ± SD 
Zeta 
Potential 
(mV) ± SD 
DPPC: Cholesterol (90:10) 106.00 ± 5.50 0.17 ± 0.02 -9.45 ± 2.58 
DPPC: DPPE-mPEG5000 (95:5) 117.80 ± 8.12 0.20 ± 0.03 -9.59 ± 1.86 
DPPC: TEL (90:10) 111.00 ± 1.30 0.27 ± 0.03 -15.50 ± 3.55 
DPPC: DOTAP (90:10) 107.53 ± 8.89 0.12 ± 0.02 +25.70 ± 7.85 
DPPC: DPPG (90:10) 115.24 ± 9.33 0.15 ± 0.02 -14.20 ± 2.82 
DPPC: Cholesterol (90:10)-mTHPC 109.60 ± 2.20 0.13 ± 0.03 -6.68 ± 0.39 
DPPC: DPPE-mPEG5000 (95:5)-mTHPC 129.40 ± 9.60 0.25 ± 0.03 -8.98 ± 2.00 
DPPC: TEL (90:10)-mTHPC 120.20 ± 3.31 0.23 ± 0.02 -13.20 ± 2.09 
DPPC: DOTAP (90:10)-mTHPC 132.56 ± 8.66 0.16 ± 0.02 +24.23 ± 12.2 
DPPC: DPPG (90:10)-mTHPC 127.71 ± 7.45 0.23 ± 0.03 -13.18 ± 5.68 
3.1.2 Encapsulation efficiency (EE%) 
The encapsulation efficiency of mTHPC loaded liposomes was determined using the 
ultracentrifugation method. The results of mTHPC encapsulation in the lipid bilayer (Table 2) 
showed that more than 70% of mTHPC was encapsulated in all the liposomal formulations. 
DPPC/Cholesterol (90:10) liposomes showed the least amount of drug encapsulated i.e. 78.0 ± 
4% which increased to highest in DPPC/TEL liposomes with an encapsulation efficiency of 
90.40 ± 2.60%. This comparative higher encapsulation can be attributed to the fact that the 
liposomes made from the polar lipid fractions of S. acidocaldarius show a remarkable stability. 
This stability of the liposomes is due to the ability of TEL to preserve membrane integrity due to 
tight membrane packing that results in retaining the entrapped molecules with a very low leakage 
problem [72]. The overall high drug load in all the liposomes can be credited to the hydrophobic 
and intermolecular interactions (hydrogen bonding) between drug and lipid molecules [85]. 
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Table 2. The encapsulation efficiency of mTHPC loaded liposomes (0.5 mg of mTHPC per 10 
mg of total lipid). Values are expressed as mean ± SD for three independent formulations (n=3). 
Liposome 
Formulation  
Theoretical drug 
load (µg/mL) 
Practical drug 
load (µg/mL) ± 
SD 
% EE 
± SD 
DPPC: Cholesterol (90:10)-mTHPC 500.00 390.49 ± 20.02 78.09 ± 4.00 
DPPC: DPPE-mPEG5000 (95:5)-mTHPC 500.00 408.54 ± 14.84 81.70 ± 3.26 
DPPC: TEL (90:10)-mTHPC 500.00 452.01 ± 19.05 90.40 ± 2.60 
DPPC: DOTAP (90:10)-mTHPC 500.00 364.40 ± 20.33 72.98 ± 6.11 
DPPC: DPPG (90:10)-mTHPC 500.00 423.48 ± 16.33 84.67 ± 2.96 
3.1.3 Morphological characterizations using AFM and Cryo-TEM 
Morphological interpretations of the mTHPC loaded liposomes were conducted using AFM and 
Cryo-TEM studies. For AFM studies, the images were acquired using intermittent contact mode 
(tapping mode). This intermittent tapping of the cantilever tip reduces the shear forces applied on 
the liposomes, which can deform or burst the vesicles. Depending on the vesicle composition, 
interactions between the sample and substrate surface (e.g. glass or silica), as well as the 
continuous oscillation of the tip, can induce the deformation of vesicles. Longer sample deposition 
times on the substrate may also lead to the formation of planner vesicles [86]. In our AFM studies, 
all the liposomes appeared to be round or slightly oval-shaped. The diameter of the particles 
resulting from the analysis of the AFM cross-sectional micrographs was found to be in good 
correlation with the hydrodynamic diameter obtained from PCS measurements (Table 1). The 
height measured view was used to analyze the liposomal size distribution parameters (Fig. 19). 
Some irregularly shaped liposomes also spread on the silicon surface like a sheet of lipid 
monolayer that might be due to the adsorption of the lipid layer the silica surface as well as the 
liposomal disruption during the preparation of samples [59].  
Cryogenic transmission electron microscopy (cryo-TEM) is a significant tool for the visualization 
of delicate ultrastructure of colloidal drug delivery systems (e.g. liposomes). It is the most widely 
used technique to study the shape, size and the overall composition of these carrier systems as it 
permits the evaluation of colloidal dispersions in the vitrified frozen state. It has an advantage that 
the rapid cooling of samples ensures minimum perturbation of the original samples [87]. 
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Figure 19. AFM micrographs (1st Row) and Cryo-electron tomographic images (3rd Row) 
showing the structural characteristics of mTHPC loaded liposomes. A) DPPC/Cholesterol B) 
DPPC/DPPE-mPEG5000 and C) DPPC/DOTAP D) DPPC/TEL E) DPPC/DPPG. For AFM 
studies, soft HQ: NSC14/AL_BS cantilevers were used to obtain the height measured images in 
trace direction. Middle pane (2nd Row) showing the cross-sectional profile of the liposomes along 
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the identified lines. The scale bar represents 500 nm scale for AFM images and 200 nm scale for 
Cryo-TEM images. 
Fig. 19(A-E) (right pane) represents the typical cryo-TEM micrographs of mTHPC loaded 
liposomes. Preparation of liposomes by extrusion resulted in the population of mainly unilamellar 
vesicles but some fractions of bi- and oligolamellar vesicles, as well as multivesicular systems 
(black arrows in Fig. 19A, D & E), can also be observed. Liposomal formulation composed of 
DPPC/Cholesterol (90:10) has predominately shown the round and slightly elliptical structures 
(Fig.  19A). This can be attributed to the presence of cholesterol as well as the tight packing of 
the vesicles under the influence of which, the liposomes tend to appear oval-shaped [87]. For the 
formulations containing DPPE-mPEG5000 in small molar fractions, disc-like associates (mixed 
micelles) can be assumed along with other vesicular structures (red arrows, Fig. 19B). These 
micelles appeared as small rods, disc or circular in shapes and can be credited to the presence of 
PEG chains in the formulation [88]. Nevertheless, the presence of discs needs more proof, because 
from the orientational point of view they should also appear as circular structures and ellipses. 
Liposomes also appeared somewhat circular and more or less polygonal in other formulations 
(Fig. 19C). This is because of the rigidity of the lipid bilayer that may influence the liposome 
shape, as the liposomes with a rigid lipid bilayer in the gel state often appear cubic or angular 
shaped particularly when the vesicles are small in size. In tetraether lipid-based formulation, 
liposomes also appeared circular or somewhat elongated (Fig. 19D). This is because of the rigidity 
of the lipid bilayer that may influence the liposome shape, as the TEL liposomes with a rigid 
membrane have the ability to preserve the membrane integrity by tight membrane packing of lipid 
molecules. 
3.1.4 In vitro cell culture experiments 
3.1.4.1 Cellular photodynamic therapy (cPDT) 
The unirradiated and photo-destruction effect of mTHPC (free as well as liposome loaded) was 
investigated in the SK-OV-3 by assessing the percentage cell viability using MTT assay. It was 
carried out in the presence of different concentrations of mTHPC liposomes for 2 h in the dark 
followed by subsequent irradiation of the cells with red light (λ=652 nm). The initial 1 h 
incubation did not show any significant effect on the cell viability (data not shown), indicated the 
need for increased incubation time. Treatment of the cells with mTHPC (dissolved in 0.1% 
DMSO) without subsequent irradiation resulted in a dose-dependent reduction of cell viability 
inferred as dark toxicity. This dark toxicity was evident at the mTHPC concentration equal to or 
51 
 
above 2.5 μM (1.7 μg/mL) (Fig. 20). In contrast, mTHPC encapsulated in liposomal formulations 
did not show any dark toxicity. These findings were in line with the previous studies conducted 
by another working group [89]. The survival of SK-OV-3 cells, incubated with different mTHPC 
concentrations and irradiated with varying light fluences is represented in Figure 20. At the light 
dose of 0.05 Jcm-2, the cell viability was reduced to less than 40% in the treated groups (except 
for DPPC/TEL and DPPC/DOTAP liposomes) as compared to untreated controls. The untreated 
control groups-maintained cell viability of 95-98% which confirms that the application of 
irradiation only, did not produce any significant cell destruction. For the formulation containing 
tetraether lipids, the cell viability was still recorded at about 60%. This could be due to the slower 
release of PS from the liposomal membrane, stabilized in the presence of tetraether lipids, while 
the lower effect produced by the DOTAP liposomes can be attributed to the slower uptake of the 
liposomes [72]. With increasing fluence, the cell viability continuously decreased in all the 
formulations, ending up at 18-20% at 1 Jcm-2. Similar dose-response curves were obtained when 
the fluence was kept constant and the concentration of mTHPC was varied between 0.05 and 5 
μM [90]. The half-maximal inhibitory concentration (IC50) of the liposomes was also reduced 
proportionally, as the fluence or PS concentration into the cells was increased. The highest 
reductions of IC50 (Table 3) were recorded in the PEGylated and DPPG containing formulations. 
The statistical evaluation using two-way ANOVA with Dunnett’s multiple comparisons showed 
that the PDT effect produced by different light fluences differed significantly (p<0.0001) to the 
unirradiated samples (dark control). 
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Figure 20. Dose-response nonlinear curves representing dark & photo-induced cytotoxicity to 
SK-OV-3 carcinoma cells. mTHPC formulations; DPPC/Cholesterol (A), DPPC/DPPE-
mPEG5000 (B), DPPC/DOTAP (C), DPPC/TEL (D), DPPC/DPPG (E) and free mTHPC 
dissolved in 0.1% DMSO (F) were incubated for 2 h and then irradiated with series of light 
exposures of 0.05, 0.5 and 1 Jcm-2 with red light (λ=652 nm). Whereas dark represents the 
formulations without irradiation. Each value is represented as the mean ± SD for three 
independent experiments. For the statistical analysis, the comparison was done against the dark 
treatment. P values (p<0.05) were considered significant and denoted as ‘****’ (p<0.0001) and 
‘**’ (p<0.01). 
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Table 3. The half-maximal inhibitory concentration (IC50) values of the photo-cytotoxicity 
induced by the mTHPC loaded liposomes and free mTHPC (dissolved in DMSO) in SK-OV-3 
cells. The IC50 values were calculated by non-linear curve fitting from the graphs and tabulated 
for the respective radiation doses (fluences). 
Formulations 
Red 
Fluence 
(J/cm2)                
λ= 652nm 
IC50  
(µM) 
Blue 
Fluence 
(J/cm2) 
λ = 457nm  
IC50 
(µM) 
DPPC/ CH.- mTHPC 
0.05 2.66 1 14.3 
0.5 0.53 5 0.64 
1 0.24 10 0.26 
DPPC/ DPPE-mPEG5000- 
mTHPC 
0.05 1.87 1 3.08 
0.5 0.35 5 0.28 
1 0.09 10 0.15 
DPPC/ DOTAP- mTHPC 
0.05 8.68 1 26.5 
0.5 2.10 5 2.65 
1 0.78 10 1.01 
DPPC/ TEL-mTHPC 
0.05 3.40 1 20.6 
0.5 0.80 5 1.46 
1 0.65 10 0.94 
DPPC/ DPPG- mTHPC 
0.05 0.17 1 6.03 
0.5 0.29 5 1.11 
1 0.14 10 0.40 
mTHPC-Std 
0.05 0.54 1 2.91 
0.5 0.13 5 1.11 
1 0.07 10 0.27 
In order to evaluate the photodynamic effect produced by mTHPC after activation at a different 
wavelength, all the formulations were irradiated with a series of light fluences at a wavelength of 
λ=457 nm. Similar to previous studies, free mTHPC (dissolved in DMSO) produced dark toxicity 
but none of the liposomal formulations affected the cell viability without application of the 
fluence [90].  
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Figure 21. Dose-response nonlinear curves representing photo-induced cytotoxicity to SK-OV-3 
carcinoma cells. mTHPC formulations; DPPC/Cholesterol (A), DPPC/DPPE-mPEG5000 (B), 
DPPC/DOTAP (C), DPPC/TEL (D), DPPC/DPPG (E) and free mTHPC dissolved in 0.1% DMSO 
(F) were incubated for 2 h and then irradiated with series of light exposures of 1 Jcm-2, 5 Jcm-2 
and 10 Jcm-2 with blue light (λ=457 nm). Whereas dark represents the treatments without 
irradiation. The half-maximal inhibitory concentration (IC50) was calculated by non-linear curve 
fitting. Each value is represented as the mean ± SD for three independent experiments. For the 
statistical analysis, the comparison was done against the dark treatment. P values (p<0.05) were 
considered significant and denoted as ‘****’ (p<0.0001) and ‘**’ (p<0.01).  
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When irradiated with a light dose of 1 Jcm-2, only liposome comprising DPPC/DPPE-mPEG5000 
was able to reduce the cell viability to 52% comparable to the photo-toxicity produced by free 
mTHPC. This could be attributed to the presence of mixed micelles and smaller liposomes in the 
formulation. These micelles are quickly taken up by the cells, the photosensitizer is release readily 
resulting in the immediate burst effect [25]. By further increasing the fluence level, the cell 
viability gradually decreased to 20% in all the formulations at a light dose of 10 Jcm-2 (Fig. 21). 
It was evident from the cell viability data obtained from photodynamic therapy, that in order to 
produce a comparable photo-destruction effect as produced by 1 Jcm-2 (when irradiated at 652 
nm), a ten-fold higher fluence (i.e. 10 Jcm-2) was required (when irradiated at 457 nm). This could 
be credited to higher light absorption, increased penetration depth (i.e. 2-3 mm as compared to 
0.3 mm in blue light) as well as the higher quantum yield of light at longer wavelength region (i.e. 
red) as described by Kiesslich et al [91]. 
3.1.4.2 Determination of reactive oxygen Species (cROS) 
In order to quantify the ROS generation and oxidative stress during the photodynamic treatment 
of the SK-OV-3 cells, the ROS assay was performed. It is based on cellular esterase-mediated 
hydrolysis of acetate group and intracellular oxidation of non-fluorescent H2DCFDA (2`,7`-
dichlorodihydrofluorescein) into green fluorescent DCF. The data obtained from the 
photodynamic mediated production of ROS is shown in Fig. 22 In our experiments, the irradiated 
liposomal formulations produced increased levels of intracellular ROS as compared to non-
irradiated ones (dark). The highest amount of ROS was produced by PEGylated liposomes owing 
to the presence of mixed micellar structures in the formulation resulting in the higher uptake of 
the PEG-PE based micellar structures [25]. Because of their smaller size, they exhibit a 
spontaneous penetration into the interstitium of tumor vasculature due to enhanced permeability 
and retention effect. Diffusion and accumulation parameters of the drug carriers in tumors have 
been shown to be highly dependent on their cut off size. The higher uptake of these mixed 
structures, in turn, deliver increased quantities of the drug to the tumor resulting in higher 
cytotoxicity [92]. It indicates the liposomes containing DPPE-mPEG5000 caused the highest 
damage to the cell as compared to other liposomes. Nevertheless, in both experiments, cells were 
irradiated at the same energy level with different wavelengths, but the amount of ROS produced 
was higher when irradiated with the red light. These results were also in line with our previous 
results obtained from the cell viability assay. It can be suggested that the production of ROS is 
very crucial for an effective photodynamic treatment of cancer cells.  
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Figure 22. Production of reactive oxygen species after dark (black bars) and photodynamic 
treatment (light grey bars) of SK-OV-3 cells with mTHPC loaded liposomes. Following 2 h 
incubation, SK-OV-3 cells were irradiated at a light dose of 1 Jcm-2 at λ = 457 nm (A) and at λ = 
652 nm. TBHP (50 µM) was used as a positive control. All the measurements were performed in 
triplicate and values were expressed as mean ± SD (n=3) 
3.1.4.3 Intracellular uptake studies 
The cellular uptake and intracellular distribution of free and liposome-bound mTHPC were 
evaluated using CLSM (Fig. 33). Therefore, SK-OV-3 cells were incubated with the different 
liposomal formulations (5 µM) at 37ºC for 2 h. A considerable localization of mTHPC was 
observed in both dark and irradiated samples. The red fluorescence of mTHPC loaded liposomes 
could be readily detected as a diffuse signal throughout the cytoplasm with particularly intense 
localization in the perinuclear region. The fluorescence distribution of the intracellular mTHPC 
did not show any significant difference between the liposomal formulations and free mTHPC 
(dissolved in DMSO). The cells were counterstained with Sytox green™ (50 nM) and were 
observed as a green fluorescent signal in the nuclear region. The co-localization of red and green 
fluorescence in the merge channel showed no sign of mTHPC localization in the nucleus. From 
the CLSM micrographs, it was observed that PEG-PE based liposome showed a comparable 
intracellular localization as that of free mTHPC which can be attributed to higher uptake of the 
combination of micelles and liposomes present in PEG-PE based formulation. On the basis of 
these observations, it was inferred that intracellular activation of mTHPC leads to the destruction 
of subcellular organelles resulting in cell death. Confocal microscopy also proved that a 
comparable fluorescence was emitted from the individual cells, which indicated the uniform 
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uptake of mTHPC by the cells. This examination could be an important prerequisite for an 
effective PDT in tumor tissue, focusing on the complete destruction of cancer cells. 
 
Figure 23. CLSM micrographs of SK-OV-3 cells incubated with 5 µM mTHPC loaded liposomes 
and free mTHPC (dissolved in DMSO) for 2 h at 37ºC. The cells were subsequently irradiated at 
652 nm with a radiation fluence of 0.05 Jcm-2. The untreated cells were taken as negative control 
(NC). The nucleus was counterstained using Sytox green™ (50 nM). The cellular uptake was 
observed using fluorescence detection filters for Sytox green™ (ex/em 504⁄ 523 nm) and mTHPC 
(ex/em. 420/ 652 nm). The scale bar represents 20 µm scale. 
3.1.4.4 In vitro genotoxicity assessment  
The comet assay is a cytogenic technique used mainly in the field of toxicological studies. 
Recently, it has also been employed in the assessment of the genotoxicity that can be caused by 
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the photodynamic treatment of the cells. The alkaline version of the comet assay is a simple and 
rapid in vitro screening method for analyzing and measuring the DNA single-strand breaks (SSB) 
or alkali labile sites [93]. The principle of the comet assay is based on the fact that DNA strands 
which occur as a negatively charged supercoiled structure in the nucleus can be fragmented due 
to the exposure to the toxins or drug treatments. These DNA SSBs are drawn towards anode under 
the influence of the electric field and appear as the olive tail. The measure of this tail moment is 
identified as the index of DNA damage. Due to the fact that photosensitizers upon administration 
may also accumulate into the normal tissue and may cause complications under low light dose or 
normal light (i.e. room or sunlight) [94]. Form Fig.24, it can be observed that no direct DNA 
strand breakage was caused by photodynamic treatment of mTHPC encapsulated liposomes as 
observed from the olive tail moment data. From the data, it was inferred that irradiation of the 
SK-OV-3 cells after treatment with a low drug or light dose (0.05 Jcm-2) did not cause any 
significant DNA damage and there was no apparent increase in the olive tail. Also, it was observed 
that there was no DNA damage in the absence of light (data not shown). From the above-
mentioned results, it can be assumed that mTHPC can be used clinically with no or minimum 
incidence of genetic toxicity [68]. 
 
Figure 24. Distribution of comet tail moment (genotoxicity) to SK-OV-3 cells obtained from 
alkaline comet assay. The cells were incubated with mTHPC loaded liposomes for 2 h at an 
equitoxic dose to produce 80% cell viability to avoid false-positive response. Irradiation was 
performed at a light dose of 0.05 Jcm-2. Each value is represented as the mean ± SD for three 
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independent experiments. For the statistical analysis, the comparison was done against the dark 
treatment. P values (p < 0.05) were considered significant and denoted as ‘****’ (p< 0.0001) and 
‘**’ (p< 0.01). 
3.1.4.5 Hemocompatibility studies 
Hemocompatibility studies serve as a critical link between in vitro and in vivo studies because the 
data obtained from these studies can be used to tailor the dosage form for the in vivo 
experiments [95]. Hemolysis assay was used to investigate the extent of erythrocyte destruction 
induced by the liposomal formulations and was conducted by estimating the amount of 
hemoglobin released after erythrocyte damage. This hemoglobin is then converted to 
oxyhemoglobin in the presence of atmospheric oxygen. The oxyhemoglobin can be detected and 
measured spectrophotometrically. This assay can be used to determine the safe concentrations that 
can be administered intravenously [58]. In our study, it was observed that all the mTHPC loaded 
liposomal formulations exhibit very low hemolytic properties as compared to the free drug 
(Fig. 25). The hemolysis potential expressed by all the formulation was below 10% while the free 
drug showed a relatively higher hemolytic effect (i.e. 25%). Activated partial thromboplastin time 
(aPTT) was performed to evaluate the effect of liposomal formulation on the coagulation time. 
The coagulation time of all the formulations was found to between 30-40 s which was well under 
the standard range. aPTT values above 50 s are clinically significant while the value above 70 s 
indicates the continuous bleeding and hemorrhage. The free drug exhibited a higher coagulation 
time of 47 s (Fig. 25). These findings suggested that our mTHPC loaded liposomal formulations 
are non-toxic as well as highly biocompatible for i.v. injection. 
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Figure 25. Hemocompatibility assay: aPTT test (left) & Hemolysis assay (right) of mTHPC 
loaded liposomes. All the formulations were tested at 10 x concentrations. Blood plasma and 
Triton™ X-100 were used as negative and positive control respectively. All the samples were 
measured in triplicate and the values were expressed as mean ± SD (n=3).  
3.1.4.6 Photo-thrombic activity of mTHPC liposomes (CAM assay) 
CAM is an alternative to in-vivo experiments that can be used to evaluate the efficacy of the 
delivery system. Vascular targeted photo-destruction of CAM is an important connection towards 
the targeting of tumor microvasculature thereby destroying the tumor tissue. To determine the 
extent of damage to the vasculature, PDT to the CAM was performed. In our experiments, it was 
observed that injection of the empty liposomes or normal saline only, produced no changes to the 
vasculature. Also, the additional application of the light dose to the CAM without prior treatment 
did not affect the integrity and profusion of the vasculature. To distinguish the changes in blood 
flow within CAM, 100 µl of mTHPC loaded liposomes were injected intravenously followed by 
irradiation of the injection site. It was observed the drug-light interval (DLI) plays a vital role in 
the photo-destruction of CAM vessels. Short DLI (e.g. 15 or 30 min) did not produce any effect 
and CAM vasculature remained intact. But when the irradiation was performed 1 h post liposomes 
injection, delayed local destruction of CAM vasculature was observed within the irradiated area. 
Typical stereographs of CAM at different time periods after i.v injection based on mTHPC loaded 
liposomes are demonstrated in Fig. 26 and 27. Nevertheless, all the formulations showed mild 
closure of smaller capillaries that onset at tpost= 10 min (data not shown), the larger vessels still 
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remain uninjured and intermittent blood flow was observed. The effect was more pronounced in 
liposome comprising of DPPC/DPPE-mPEG5000 followed by DPPC/DPPG liposome. At tpost= 60 
min, a complete occlusion of large vessels with the characteristic decline in blood flow was 
visible. These findings were in line with the previous observations regarding in-ovo PDT [96]. 
Ultimately at tpost= 24 h, a complete destruction of CAM vasculature at the irradiated area was 
evident. Scar formation due to the effective closure of all the blood vessels was observed in the 
CAM after 24 h of the treatment while the embryo still survived. There was a mild or no effect 
observed when free mTHPC (dissolved in PBS/ DMSO) was injected. This could be attributed to 
the dimerization of drug molecules that resulted in the reduction of its efficacy. 
z  
Figure 26. Stereomicrographs of CAM representing PDT mediated scar formation due to the 
effective closure of CAM vasculature at the irradiated area. The observations were continued till 
48 h after that experiment was terminated. The embryo still survived the treatment indicating the 
local destruction of the vasculature. The irradiation was performed at a light dose of 4.8 Jcm-2 
using a red laser diode (652 nm, 40 mW) with Weber needle. The scale bar represents the 500 µm 
scale. 
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Figure 27. Typical stereomicrographs of CAM representing PDT mediated occlusion of CAM 
vasculature. Images were acquired before (dark), immediately after irradiation (tpost = 0 min) and 
at tpost 10, 40- and 60-min post i.v injection of mTHPC loaded liposomes 0.5mg mTHPC/10mg of 
lipids). Irradiation was performed at a light dose of 4.8 Jcm-2 using a red laser diode (652 nm, 40 
mW) with Weber needle. The scale bar represents the 500 µm scale. 
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3.2 Lipid coated polymeric nanoparticles:  
3.2.1 Physicochemical characterizations:  
In the current study, PLGA nanoparticles were prepared utilizing emulsion solvent evaporation 
technique. Two different sizes of THP loaded PLGA nanoparticles (i.e. 200nm and 400nm) were 
prepared to compare their physicochemical properties and efficacy against the cancer cells. After 
the pilot study, the PVA concentrations were optimized to be 1% and 0.3% to produce 200nm and 
400nm particles respectively, while maintaining all the other parameters constant. The particle 
size distribution and their surface charges are exhibited in Table 1. It can be observed that THP 
NP showed a narrow size distribution of 194.9 ± 2.7 nm and a low polydispersity index of 0.08 ± 
0.02 as compared to PIR NP. This was due to the presence of a higher concentration of the 
emulsifier in THP NP causing the formation of stable emulsion with smaller and uniform droplet 
size, leading to the formation of smaller sized nanoparticles with low polydispersity index. The 
lower concentration of PVA in PIR NP not only produced a higher particle size of 373.4 ± 8.8 nm 
but the polydispersity index was also high indicating a bimodal distribution of particles (i.e. 0.23 
± 0.02) [52]. The addition of the THP in the nanoparticle formulations produced a slight increase 
in the particle size (10-15nm approximately) and size distribution. All the nanoparticle 
formulations exhibited a positive surface charge ranging from 8.3 ± 1.6 mV to 10.5 ± 1.7mV, 
owing to the presence of a small amount of chitosan in the formulations. 
The composition of prepared liposomes and their physicochemical properties are presented in 
Table 4. The hydrodynamic diameter was determined to be 100.5 ± 3.4 nm with a PDI of 0.19 ± 
0.06 representing the narrow monomodal distribution of liposomal vesicles. mTHPC loaded 
liposomes showed a slightly higher hydrodynamic diameter and PDI. This could be due to the fact 
that mTHPC orientate itself in the bilayer membrane and interacts with the polar heads of lipids 
through the hydrogen bonding leading to a slight increase in vesicle size [85]. Liposomal 
formulation possessed an overall negative zeta potential (-12.9 ± 0.5 mV). The lipid enveloped 
nanoparticle was produced by coating the THP NP with the mTHPC loaded PEGylate liposome 
(i.e. DPPC/DPPG /mPEG-DPPE-5000). The hydrodynamic diameter of LCNP was found to be 
208.6 ± 2.2 nm with no significant increase in the PDI. A small increase in the hydrodynamic 
diameter (i.e. 4 nm) of the LCNP was observed when compared to uncoated PLGA NP. Assuming 
the thickness of the lipid membrane to be about 4-5 nm, our results were in line with the previous 
experiments done by our workgroup [54]. 
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Table 4. Physicochemical properties of THP loaded PLGA nanoparticles, mTHPC loaded 
liposomes, and lipid-coated nanoparticles (LCNP). Each THP loaded PLGA nanoparticle contains 
2 mg of THP and 100 mg of PLGA. Each liposome consists of 0.5 mg of mTHPC in 10mg of 
total lipids. Hydrodynamic diameter is expressed as a function of particle size distribution by 
intensity. Values are expressed as mean ± S.D for three independent measurements (n=3). 
Formulations Diameter [nm] PDI ζ Potential [mV] 
PLGA NP  194.9 ± 2.7 0.08 ± 0.02 8.3 ± 1.6 
THP NP  204.7 ± 3.4 0.10 ± 0.03 7.6 ± 1.6 
NP-Blank 373.4 ± 8.8 0.23 ± 0.02 8.6 ± 1.4 
PIR NP  405.7 ± 10.0 0.23 ± 0.06 10.5 ± 1.7 
LP-Blank 100.5 ± 3.4 0.19 ± 0.06 -12.9 ± 0.5 
mTHPC-LP 108.8 ± 2.1 0.21 ± 0.02 -12.7 ± 1.2 
LCNP 208.6 ± 2.2 0.11 ± 0.01 5.9 ± 1.1 
3.2.2 Encapsulation efficiency: 
The encapsulation efficiency of the THP loaded PLGA nanoparticles and mTHPC loaded 
liposomes were determined using the solvent extraction method. For this purpose, unentrapped 
drugs from the nanoparticles and liposomes were removed using centrifugation and 
ultracentrifugation technique respectively. A direct method of dissolving the nanoparticle or 
liposomal drug pellet was used and ultimately the actual amount of THP in PLGA nanoparticles 
and mTHPC in liposomes was measured. Being a highly lipophilic molecule, mTHPC tends to 
align itself in the hydrophilic milieu of the liposome and showed an overall high drug loading of 
80.5 ± 5.1 % [83, 85]. Similarly, the optimized nanoparticle formulations also showed a relatively 
high encapsulation efficiency (EE) with THP NP showing an EE of 86.5 ± 4.5% and PIR NP 
showing EE of 74.3 ± 5.4%. This higher EE can be explained due to the fact that both, the THP 
and PLGA are soluble in ethyl acetate employed for the nanoparticle preparation [53]. 
3.2.3 Morphological characterizations: 
3.2.3.1 Atomic force microscopy (AFM) 
Morphological characterizations were conducted using atomic force microscopy (AFM) and 
transmission electron microscopy (TEM). AFM studies were carried out using intermittent contact 
mode and images were acquired in height measured trace, lock in amplitude as well as lock in-
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phase mode. Fig. 28 shows the typical AFM monographs of mTHPC loaded liposomes, THP 
loaded nanoparticles and lipid-coated polymeric nanoparticles. The AFM micrographs manifested 
perfectly round shaped mTHPC liposomes as well as THP loaded nanoparticles. The height 
measured view was used to analyze the size distribution parameters of the nanocarriers. Some 
irregularly shaped liposomes also tend to spread on the silicon surface like a sheet of lipid 
monolayer that might be due to the liposomal disruption during the preparation of samples. The 
AFM size investigations were in correlation with the hydrodynamic diameter obtained from DLS 
studies. A uniform distribution of the THP nanoparticles (Fig. 28A-a) with a smooth surface can 
be seen which represents the unimodal distribution of the nanoparticles in the formulation [59, 
97]. Whereas, PIR NP showed a tendency to aggregate forming clusters. This explains the broad 
range of particle sizes and the high polydispersity observed. This agglomeration tendency was 
likely due to insufficient steric stabilization by the PVA (Fig 28A-b). The lipid layer on the 
nanoparticle surface can also be visualized with AFM images (Fig. 28B). In some places, the 
nanoparticles are not completely covered with the lipid bilayer and show some gaps in between 
the coating. The thickness of the absorbed lipid bilayer was determined from these gaps and was 
found to be in the range (i.e. 4-5nm) [54].  
3.2.3.2 Transmission electron microscopy (TEM) 
Transmission electron microscopy (TEM) is the most widely used technique to study the size, 
shape, and morphology of the carrier system. TEM allows the imaging of the liposomes and 
nanoparticles in their original form, without further need of the sample modification (e.g. labeling, 
fixation, etc.). The samples were negatively stained using 2% uranyl acetate. Fig. 29 shows the 
representative TEM micrographs of the mTHPC loaded liposomes (Fig. 29a), THP loaded PLGA 
nanoparticles (Fig. 29b) and lipid-coated nanoparticles (Fig. 29e). TEM observations revealed 
mostly circular unilamellar lipid vesicles [58]. In addition, some irregularly shaped liposomes can 
also be seen in the formulation which could be caused by the quick drying of the liposomes during 
the staining process as the PEG conjugated DPPE and DPPC were stained using this dye to 
enhance electron density and improve the image contrast. 
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Figure 28. Illustration of surface morphology of A): THP NP a); PIR NP b) and mTHPC- LP 
using AFM. Pane B) represents the AFM micrographs of lipid-coated nanoparticles a1-2) height 
measured view; b1-2) lock-in amplitude view and c1-2) lock-in phase view. HQ: NSC14/AL_BS 
cantilevers tips were used for liposomes while HQ: NSC16/AL_BS cantilevers were used for the 
uncoated and coated nanoparticles. The scale bar represents 500 nm scale. 
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Figure 29. Typical TEM micrographs of nanoformulations including a) mTHPC-LP; b) THP NP 
and c) LCNP. The samples were stained with 2% uranyl acetate for 5min prior to imaging. The 
scale bar represents a 250 nm scale. 
Furthermore, polymeric nanoparticles with a lipid layer adsorbed on their surface as a dim ring 
surrounding the polymeric core-shell of hybrid carriers can also be observed clearly [98]. This 
lipid coating is the result of the non-covalent weak electrostatic attractions between the lipid 
bilayer and polymeric nanoparticles. The size of these liposomes and lipid-coated vesicles 
obtained by TEM micrographs was in good agreement with the size distribution obtained by 
particle size analyzer [98, 99]. 
3.2.4 In vitro drug release profile: 
The in vitro drug release from the pirarubicin loaded PLGA nanoparticles was conducted in PBS 
(pH 7.4) containing 1% tween 80. Tween 80 is a commonly used nonionic emulsifier used to 
enhance the solubilization of the hydrophobic drug by the formation of the micelles. Because of 
the very low aqueous solubility of pirarubicin, the addition of this solubility enhancing component 
was necessitated to ensure the sink conditions and to achieve detectable UV/VIS concentrations 
during the release studies [53]. The drug release mechanisms are important as the drug-polymer 
formulation because of the proposed application in sustained drug delivery. Different drug release 
mechanisms from PLGA nanoparticles have been reported including: (a) the desorption of the 
drug absorbed to the particle surface, (b) diffusion through the nanoparticle matrix, (c) erosion of 
nanoparticle matrix and (d) combination of diffusion and erosion. In order to manipulation the 
drug release from the polymer matrix, a complete understanding of these mechanisms is required 
[100]. The drug release from the PLGA nanoparticles is shown in Fig. 30. It is evident that the 
pirarubicin loaded PLGA nanoparticles followed a typical biphasic drug release pattern from the 
nanoparticle matrix with an initial burst release of 40% for THP-NP and 32% for PIR-NP within 
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first 24 h. This burst release was followed by a sustained release of the drug from polymer matrix 
over the period of 7 days. This initial phase of drug release is mainly attributed to desorption or 
diffusion of the drug located at the large surface of the nanoparticles or loosely bound with the 
polymer matrix. The remaining unreleased drug was assumed to be tightly associated with PLGA 
molecules and/or well entrapped within the nanoparticle matrix and occurs mainly by diffusion 
or erosion of the matrix under sink conditions. If the diffusion of a drug is faster than matrix 
erosion the mechanism of release is largely controlled by a diffusion process [101]. It was also 
observed that PIR-NP (i.e. 400nm) showed a lower cumulative drug release of 57% till the end of 
the experiment contrary to the THP-NP (i.e. 200 nm) which showed a relatively higher cumulative 
release of 72%. This could be explained by the fact that in case of smaller nanoparticles, the 
greater surface area produces a higher number of drug molecules at the surface of nanoparticles 
ready for faster release [102].  
 
Figure 30. Cumulative drug release [%] of pirarubicin from PLGA nanoparticles (THP-NP & 
PIR-NP) in PBS (pH 7.4) buffer containing 1 % v/v tween 80% to assure sink conditions. The 
samples were withdrawn at specified time intervals were analyzed spectrophotometrically. The 
results are expressed as mean ± SD for three independent experiments (n=3). 
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3.2.5 In vitro cytotoxicity synergism 
The in-vitro cytotoxicity synergism of LCNPs, as well as the cell viability of the SK-OV-3 cells 
after being treated with THP, loaded PLGA nanoparticles, mTHPC loaded liposomes, and free 
THP/mTHPC (dissolved in DMSO) was determined using MTT assay. It was done by incubating 
the cells in the presence of different concentrations of the nanoformulations as well as of the free 
drugs for 4 h. This was followed by subsequent irradiation of the cells at λ=652 nm (except for 
free THP and THP loaded nanoparticles). The results of the cytotoxicity assay are expressed in 
Fig. 31. It is evident from the results that the presence of free THP or THP loaded biodegradable 
nanoparticles caused a reduction in the SK-OV-3 cell viability with the highest reduction observed 
at the dose of 100μM (Fig. 31A). The highest cytotoxicity was produced by the free THP (72.26 
± 5.40%) followed by THP NP (62.14 ± 3.13%). The least effect was observed with PIR NP with 
the cell viability still recorded at 52.56 ± 5.50%. This can be attributed to the slower uptake of the 
larger particles (i.e. 400 nm) as the particle size ranging from 100-200 nm are appropriate for 
effective cellular uptake and consequently for the higher anticancer activity. It was also observed 
that free THP dissolved in the DMSO showed higher cytotoxicity, which could be referred to as 
the controlled release properties of PLGA nanoparticles as the rate-limiting step.  
The treatment of the cells with free mTHPC (dissolved in 0.1% DMSO) without subsequent 
irradiation resulted in a slight reduction of cell viability (18.51± 1.87%). This dark toxicity was 
evident only at the highest mTHPC concentration (i.e. 5 μM) (Fig. 31B). Contrary to this, mTHPC 
did not show any dark toxicity when encapsulated in a liposomal formulation suggesting the safety 
of the formulation (Fig. 31C). These findings were also in accordance with the previous studies 
conducted by our research group. It is also evident that with the increase in light fluence, the cell 
viability continuously decreased ending up at 18-20% at 350 mJcm-2 [89]. Similar results were 
obtained when the mTHPC encapsulated liposome was coated over THP loaded PLGA 
nanoparticles. The LCNPs without succeeding irradiation exhibited cell viability of 32.2± 1.3% 
which was relatively less as compared to the THP nanoparticles alone (i.e. 37.8± 3.1%). This 
effect can be attributed to higher cellular uptake of the lipid-coated particles as compared to the 
uncoated nanoparticles [103]. The dose-response cell viability curves obtained from the LCNPs 
treated cells manifested higher cell destruction as compared to mTHPC liposomes or THP 
nanoparticles alone (Fig. 31D). This higher anticancer effect can be credited to the synergistic 
effect produced by both the drugs combined in one nanocarrier system [79]. The half-maximal 
inhibitory concentration (IC50) of the formulations was also reduced proportionally, as the light 
or drug dose into the cells was increased. The statistical evaluation using two-way ANOVA with 
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Dunnett’s multiple comparisons showed that the PDT effect produced by different light fluences 
differed significantly (p<0.0001) to the unirradiated samples. 
 
Figure 31. Dose-response curves representing cell viability of SK-OV-3 carcinoma cells. 
Cytotoxicity induced by THP loaded nanoparticles and free THP (A); dark and photo cytotoxicity 
induced by free mTHPC (B); mTHPC-LP (C); and lipid-coated nanoparticles (LCNP) (D). In all 
cases, the free drug was dissolved in 0.1% DMSO. The cells were incubated for 4 h with the 
formulations at 37°C and then irradiated (except A) with radiation fluence of 50 mJcm-2 and 350 
mJcm-2 at λ=652 nm. Dark was used as the negative control and represents cells without 
irradiation. The half-maximal inhibitory concentration (IC50) was calculated by non-linear curve 
fitting. Each value is represented as the mean ± SD for three independent experiments (n=3). 
Table 5. The half-maximal inhibitory concentration (IC50) values of the MTT assay induced by 
Pirarubicin loaded PLGA nanoparticles and photo-cytotoxicity induced by the THPC loaded 
71 
 
liposomes, free mTHPC (dissolved in DMSO) as well as LCNPs in SK-OV cells. The IC50 values 
were calculated by non-linear curve fitting from the graphs and tabulated for the respective 
radiation doses (fluences). 
Formulations 
Light Dose  
[mJ/cm2] 
IC50 [µM] 
Free THP (dissolved in DMSO) - 6.750 
THP PLGA NP-1 - 14.37 
THP PLGA NP-2 - 27.51 
Free mTHPC (dissolved in DMSO) 
50 
350 
1.962 
0.422 
DPPC/DPPG/mPEG-DPPE5000 
50 
350 
1.947 
0.349 
LCNP 
50 
350 
0.414 
0.187 
3.2.6 Assessment of reactive oxygen species (ROS): 
The production of ROS has a very crucial effect on the results of combination therapy as the high 
production of ROS induces significant damage to the biomolecules (i.e. nucleic acids, proteins, 
etc.) in the cancer cells. In order to determine the effect of combination therapy on the intracellular 
ROS production in the SK-OV-3 cells, the ROS assay was performed. For this purpose, one of 
the commonly used molecular probe H2DCF was used. Esterified form of this dye is non-
fluorescent and cell-permeable, thus can enter the cells freely. Inside the cell, it gets deacetylated 
into the cell impermeable dye by the action of cell-bound esterases and then gets oxidized by 
intracellular ROS into a green fluorescent DCF [104]. The fluorescence intensity corresponds to 
the ROS production is then detected using fluorescence microscopy. The data obtained from the 
production of ROS after being treated with formulations and free drugs is shown in Fig. 32. In 
our experiments, the irradiated liposomal formulation or free drug (dissolved in DMSO) produced 
increased levels of intracellular ROS as compared to non-irradiated one (dark). These findings 
were in line with the cytotoxicity experiments in which unirradiated formulations or free drug did 
not produce a significant reduction in cell viability [65]. The highest amount of ROS was produced 
by PEGylated liposomes coated over the THP loaded nanoparticles giving a synergistic effect for 
the production of ROS. The reason for higher ROS production by the lipid-coated nanoparticles 
can be explained by the higher cellular uptake of these particles as compared to uncoated particles 
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[103]. The fact that the highest damage to the cancer cells was done by lipid-coated THP 
nanoparticles could be explained by this higher ROS production. As expected, the amount of ROS 
produced by uncoated THP nanoparticles and free THP, before and after irradiation remained the 
same and no significant difference in the ROS levels was observed. 
 
Figure 32. Production of ROS in response to mTHPC loaded liposomes, free mTHPC, THP 
loaded PLGA nanoparticles, free THP and Lipid coated polymeric nanoparticles (LCNP). 
DCFDA (25 μM) was used as a free radical quenching fluorescent dye. The cells were incubated 
with the formulations or free drug for 4 h at 37 ºC. Subsequent radiation was performed at a light 
dose of 0.5 J/cm2 (λ = 652 nm). Blank represents the untreated cells whereas TBHP (50 μM) was 
used as a positive control. All the measurements were performed in triplicate and values were 
expressed as mean ± S.D (n=3). For the statistical analysis, the comparison was done against the 
blank group. P values (p < 0.05) were considered significant and denoted as ‘***’ (p< 0.001), ‘**’ 
(p< 0.01) and ‘*’ (p<0.1). 
3.2.7 Hemocompatibility assay 
Hemocompatibility of the synthesized nano-formulations is a significant criterion for 
pharmaceutical and biomedical applications. It involves the necessary evaluation of the hemolytic 
potential of drug formulations with blood components which would, in turn, determine their 
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therapeutic efficacy and in vivo fate. These studies also serve as a critical link between in vitro 
and in vivo studies because the data obtained from these studies can be used to tailor the dosage 
form for the in vivo experiments. The hemolytic potential of our drug formulations was assessed 
to evaluate their safe concentrations that can be administered intravenously. It was done by 
estimation of the hemoglobin release after erythrocyte damage caused by drug formulations. The 
atmospheric oxygen then converts this hemoglobin into oxyhemoglobin which can be detected 
spectrophotometrically [105]. The results of the hemocompatibility studies are expressed in Fig. 
33.  In our study, it was observed that both of the free drugs showed a relatively higher hemolytic 
effect (i.e. 14% and 20% for free mTHPC and THP respectively) even at a lower dose, while the 
degree of hemolytic toxicity exhibited by all the formulations was less than 10% including lipid-
coated nanoparticles (i.e. 8.93 %). This indicates that our formulations were less hemotoxic and 
had improved biocompatibility with the blood components. The aPTT test was performed to 
evaluate the effect of nanoformulations on the coagulation time of blood. An increase in aPTT 
time was observed in the case of free drugs (127.7 s and 60.2 s for free THP and mTHPC 
respectively). It is important to consider that the aPTT values above 50 s are clinically significant 
while the value above 70 s indicates the continuous bleeding and hemorrhage. Contrary to the free 
drugs, the coagulation time depicted by the nanoformulations was found to between 39.5 s – 46.8 
s which was well under the standard range [106, 107]. The aPTT values exhibited by the drug 
formulations were also comparable to that of the blank (i.e. 37.2 s). These findings suggested that 
our nanoformulations were biocompatible as well as non-toxic for i.v. injection. 
 
Figure 33. Hemocompatibility assay A) aPTT assay & B) Hemolysis assay of mTHPC loaded 
liposomes, THP loaded PLGA nanoparticles, Lipid-coated nanoparticles (LCNP) and free 
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mTHPC/ free THP (dissolved in DMSO). Triton X-100 was used as a positive control for 
hemolysis assay was considered as 100% hemolysis. Blood plasma was considered as blank in 
the case of hemolysis assay while erythrocytes were considered as blank in the aPTT test. All the 
samples were measured in triplicate and the values were expressed as mean ± S.D (n = 3).  
3.2.8 Alkaline comet assay 
Single-cell gel electrophoresis (SCGE) is a simple, sensitive and most extensively used technique 
for assessing DNA damage (DNA strand breaks) in eukaryotic cells. It has achieved the status of 
a standard test to explore the safety of the drug formulations. This test is based on the fact that the 
integrity of the cellular components gets compromised on exposure to genotoxic chemicals. DNA 
chromosomes get damaged on long term exposure and after segregation, they move towards the 
anode under the influence of electricity. This movement is detected by fluorescence microscopy 
and regarded as the tail moment [68, 93]. The measure of this tail moment is indexed as the degree 
of DNA damage. The results of the comet assay are shown in Fig. 34. It is evident from the results 
obtained that the highest genotoxicity was caused by the free drugs (free THP and mTHPC) when 
exposed to the SK-OV-3 cells but still categorized in the class II damage (i.e. 5-20%; low 
damage). On the other hand, none of the formulations, including the lipid-coated nanoparticles 
induced any direct DNA damage and were classified under class-I (i.e. 0-5%; no DNA damage) 
as observed from the olive tail moment data [108]. From the data, it was concluded that irradiation 
of the SK-OV-3 cells after treatment with a low drug or light dose did not cause any significant 
DNA fragmentation and there was no apparent increase in the olive tail. Tail lengths of different 
comets were statistically analyzed using one-way ANOVA. Dunnett’s post hoc test with multiple 
comparisons against control (blank) was used to compare the results. The results were significant 
when compared to control with a p-value of < 0.05. The % DNA in the comet tail was almost the 
same as one of the negative controls, even although a statistically significant effect was observed. 
In conclusion, the present study clearly indicated that the lipid-coated PLGA nanoparticles can be 
used clinically with no or minimum incidence of genetic toxicity if accumulated in peripheral 
organs in a small amount. 
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Figure 34. Distribution of comet tail moment representing the genotoxicity to SK-OV-3 cells 
obtained from alkaline comet assay. The cells were incubated with mTHPC loaded liposomes, 
THP loaded PLGA nanoparticles, LCNP and free mTHPC/ free THP (dissolved in 0.1% DMSO) 
for 4 h at an equitoxic dose. Irradiation was performed at a light dose of 0.05 J/cm2. Each value is 
represented as the mean ± S.D for three independent experiments. For the statistical analysis, the 
comparison was done against the untreated cells. P values (p < 0.05) were considered significant 
and denoted as ‘***’ (p< 0.001) and ‘**’ (p< 0.01). 
 
Figure 35.  Representative fluorescence micrographs genotoxicity to SK-OV-3 cells obtained 
from alkaline comet assay 
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3.2.9 Cellular uptake pathway analysis 
To study the internalization mechanism of nanoformulations in the SK-OV-3 cells, the inhibitors of 
the cellular uptake pathways were used. Two major pathways utilized for the internalization of the 
nanocarriers includes the clathrin-dependent endocytosis and caveolin dependent pathway. Clathrin 
dependent endocytosis is selectively obstructed by Chlorpromazine which acts by inhibiting the 
formation of clathrin-coated vesicles that are formed by the clathrin-coated pits leading to the 
formation of endosomes which ultimately fuse with the lysosomes. Chlorpromazine is also supposed 
to interfere with the intracellular processing of the clathrin. Caveolin dependent mechanism is 
inhibited by Filipin-III. It is a macrolide antibiotic derived from the Streptomyces filipensis and acts 
by interfering with cholesterol mediated endocytic functions thereby inhibiting the lipid raft or 
caveolae endocytosis [53]. Fig.36 demonstrates that the incubating the cells without 
nanoformulations and/or with inhibitors only did not cause any decline in the cell viability. Whereas, 
the cells incubated with nanoformulations without any inhibition showed a substantial reduction in 
cell viability. Furthermore, when the cells were preincubated with chlorpromazine, a considerable 
increase in the cell viability was observed due to the inhibition of clathrin-dependent uptake pathway. 
Additional incubation with Filipin-III showed relatively less inhibition of nanoformulations uptake. 
This inference leads to the presumption that nanoformulations uptake occurred mainly through 
clathrin-mediated endocytosis. None of the inhibitors was able to minimize the uptake of the free 
mTHPC and/or free THP (dissolved in DMSO). This result leads to the inference that the free drugs 
were not internalized by any of the said mechanisms. Instead, they were taken up by the cells through 
the diffusion process. These findings were in agreement with the earlier studies elaborating that the 
lipid particles are mainly internalized via clathrin-dependent pathways and are highly dependent on 
cell type [57, 109]. 
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Figure 36. Cellular uptake mechanism of the nanoformulations in SK-OV-3 cells in the presence 
of specific inhibitors (i.e. 15 µM Filipin III and 30 µM Chlorpromazine). After pre-incubation 
with the inhibitors, the cells were then incubated with mTHPC loaded formulations (mTHPC-LP 
& LCNP) or free mTHPC (dissolved in DMSO) at a concentration of 1.5 μM as well the THP 
loaded formulations (THP-NP & LCNP) or free THP (dissolved in DMSO) at a concentration 
equivalent to 50 μM for 4 h. The irradiation was performed at a light dose of 0.5 Jcm-2 (for mTHPC 
loaded formulations). The viability of untreated cells was considered as 100%. Blank represents 
cells without any inhibitor. values are represented as the mean ± SD for three independent 
experiments.  
3.2.10 Apoptosis assay using flow cytometry 
Apoptosis also known as programmed cell death, is a normal process of the health and 
development of multicellular organisms. Unlike necrosis, which is considered as accidental or 
traumatic cell death and is mainly caused by acute cellular injury, apoptosis is a well-regulated 
and controlled process and gives advantages during the life cycle. It is mainly characterized by 
the morphological and biochemical changes including the compaction and fragmentation of the 
nuclear chromatin, cell surface blebbing, shrinkage of the cytoplasm and the loss of membrane 
asymmetry [110, 111].  In order to evaluate the synergistic apoptosis by flow cytometry 
(Fluorescence-activated cell sorting: FACS), one group of the cells was treated mTHPC loaded 
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liposomes and group two was treated with free mTHPC (dissolved in DMSO). Similarly, the 3rd 
group was treated with the THP loaded PLGA nanoparticles while group four was treated with 
the free THP (dissolved in DMSO). For the synergistic effect, group five was treated with the 
lipid-coated nanoparticles. The cells without any treatment but with the sequential irradiation as 
that of the other groups were considered as negative control. The results of the apoptosis assay 
are expressed in Fig. 37 represents the typical FACS micrographs of the flow cytometry. It was 
noticed that combining the cell treatment in the form of LCNPs had a pronounced apoptotic effect 
in the SK-OV-3 cells as compared to treatment with a nanocarrier having only one drug. The 
results also demonstrated that the cells which were treated with free mTHPC, mTHPC-LP, free 
THP or THP-NP manifested 54.57%, 39.37%, 58.22% and 54.39% apoptotic cells (early + late 
apoptosis; Q1+Q2) respectively. On the other hand, a synergistic treatment subsequently 
increased the cell apoptosis i.e. 70.71% which was comparable to the combined cellular apoptosis 
produced by the mTHPC-LP and THP-NP treatment. This could be attributed to the fact that 
increased amount of ROS generated due to combined chemo-photodynamic effect of LCNPs 
induced a synergistic apoptotic effect in the cells [112, 113]. These results were also in a good 
correlation with the results obtained from the quantitative ROS assessment and cell viability data 
obtained previously.   
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Figure 37. Apoptosis assay (FACS micrographs) in SK-OV-3 cell line by nanoformulations 
(mTHPC-LP, THP-NP and LCNP) as well as with free mTHPC/THP treatment. Here the top left 
(Q1) = early apoptotic cells, top right (Q2) = late apoptotic cells, bottom right (Q3) = d dead cells, 
and bottom left (Q4) = represents the healthy cells. The cells irradiated with equivalent light dose 
and without any treatment were considered as the negative control.  
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Figure 38. Apoptosis assay (graphical representation) by flow cytometry in SK-OV-3 cell line by 
nanoformulations (mTHPC-LP, THP-NP, and LCNP) as well as with free drugs (mTHPC/THP; 
dissolved in DMSO). Graphical representation of % positive cells (live, dead, early apoptotic and 
late apoptotic, respectively).  
3.2.11 Stability studies in simulated conditions 
Serum stability studies were performed to check the effect of serum protein on the formulations. 
The stability of the particles is based not only on the physical characteristics of the encapsulated 
agent and the carrier system but also on the biological environment with which they are placed. 
The adsorption of serum proteins on the formulations was estimated by DLS and LDA analysis. 
In order to simulate the physiological conditions, the formulations were incubated with 60% FCS 
and PBS (pH 7.4) in a shaking incubator at 37°C. The results manifested a reduction in the particle 
size of all the formulations (i.e. THP NP, mTHPC-LP and LCNP) after being incubated in the 
serum for 24 h (Table 7). This could be attributed to the release of surface-bound THP resulting 
in the reduction of nanoparticle size [114]. Furthermore, the decrease in the hydrodynamic 
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diameter of the particles could be due to the fact that serum proteins interact with the particles via 
osmotic forces which causes the shrinkage of the particle size [115]. Interestingly, the zeta 
potential of THP NP and lipid-coated PLGA particles was negative when placed in 60% serum, 
suggesting the adsorption of serum proteins. This result could be attributed to the fact that the 
serum is composed of negatively charged proteins which tend to adsorb more on the surface of 
the charged particle as compared to the neutral ones resulting in the reduction of the surface charge 
[116]. The increase in the PDI of the particles can be attributed to the reduction of the homogeneity 
of formulations. The changes in PDI were independent of the particle size.  
Table 6. The changes in the physicochemical parameters of nanoformulations (THP loaded PLGA 
nanoparticles, mTHPC encapsulated liposomes, and lipid-coated nanoparticles). The formulations 
were incubated with PBS (pH 7.4; without Ca2+/Mg2+) at 37ºC for 24 h in a shaking incubator. 
Hydrodynamic diameter is expressed as particle size distribution by intensity. The results are 
expressed as mean ± SD (n=3). 
Formulation Time [h] 
Diameter 
 [nm] ± SD 
PDI ± SD 
ζ Potential 
[mV] ± SD 
THP NP 
0 
1 
4 
24 
204.7 ± 3.4 
212.4 ± 3.4 
220.2 ± 7.4 
202.7 ± 3.5 
0.10 ± 0.03 
0.12 ± 0.02 
0.13 ± 0.03 
0.08 ± 0.02 
7.60 ± 0.34 
6.18 ± 0.19 
5.27 ± 0.19 
6.28 ± 0.24 
mTHPC-LP  
0 
1 
4 
24 
108.8 ± 2.1 
105.4 ± 9.5 
115.0 ± 9.3 
122.7 ± 8.9 
0.19 ± 0.06 
0.21 ± 0.07 
0.23 ± 0.01 
0.22 ± 0.01 
-12.90 ± 0.5 
-12.60 ± 1.0 
-15.50 ± 3.4 
-14.00 ± 2.7 
LCNP 
0 
1 
4 
24 
208.6 ± 2.2 
212.6 ± 4.8 
220.5 ± 7.1 
205.3 ± 3.7 
0.11 ± 0.01 
0.15 ± 0.04 
0.17 ± 0.02 
0.13 ± 0.04 
5.90 ± 0.90 
4.24 ± 0.37 
4.63 ± 0.59 
4.39 ± 0.23 
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Table 7. The changes in the physicochemical parameters of THP loaded PLGA nanoparticles, 
mTHPC encapsulated liposomes, and lipid-coated nanoparticles. All the formulations were 
incubation with FCS (60%) at 37ºC for 24 h in a shaking incubator. Hydrodynamic diameter is 
expressed as particle size distribution by intensity. The results are expressed as mean ± SD (n=3). 
Formulation  Time [h] 
Diameter 
[nm] ± SD 
PDI ± SD 
ζ Potential 
[mV] ± SD 
THP NP 
0 
1 
4 
24 
204.7 ± 3.4 
195.5 ± 4.3 
191.8 ± 4.7 
179.3 ± 3.8 
0.10 ± 0.03 
0.21 ± 0.02 
0.22 ± 0.04 
0.22 ± 0.01 
7.60 ± 1.4 
-10.41 ± 1.2 
-15.42 ± 1.2 
-15.92± 1.3 
mTHPC-LP  
0 
1 
4 
24 
108.8 ± 2.1 
113.2 ± 2.6 
105.5 ± 4.5 
101.7 ± 3.4 
0.19 ± 0.06 
0.25 ± 0.01 
0.27 ± 0.03 
0.32 ± 0.03 
-14.68 ± 1.4 
-13.22 ± 0.5 
-15.05± 0.8 
-15.73 ± 0.9 
LCNP 
0 
1 
4 
24 
208.6 ± 2.2 
191.6 ± 9.8 
180.5 ± 3.1 
176.5 ± 1.9  
0.11 ± 0.01 
0.22 ± 0.02 
0.19 ± 0.02 
0.21 ± 0.01 
5.90 ± 0.9 
-14.61 ± 1.1 
-15.75 ± 1.0 
-15.31 ± 0.7 
3.2.12 In vivo experiments 
3.2.12.1 In vivo acute toxicity assessment 
 The safety and tolerability of the nanoformulations were tested relative to the treatments in mice 
with weight loss, serum biochemical analysis and histopathological examinations used as 
assessment parameters for the in vivo toxicity studies. The formulations were administered 
intravenously via tail vein to Swiss albino mice at a dose of 5 mg/kg and 0.150 mg/kg of body 
weight for THP and mTHPC respectively [117, 118]. During 48 h of observation, the mice did 
not show any sign of toxicity as examined from the behavioral patterns, skin, urine color, 
respiration, and sleep patterns. The same parameters were monitored every day to examine any 
signs of toxicity. Throughout the course of the study, no mortality or any significant change in the 
body weight was observed confirming the safety of our nanoformulations. Post 7 days, the blood 
was collected and the mice were euthanized to remove the body organs for histopathological 
studies [77]. 
3.2.12.2 Body visceral index  
Body visceral index is considered as one of the effective indicators of chemically induced changes 
to the organs. The comparison of organ weight between the untreated and treated animal groups 
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can be used to evaluate the toxicity profile of the drug formulations [118]. Post 7 days treatment, 
the organ to body weight ratios (visceral indices) of vital body organs including liver, kidney, 
lungs, and heart were determined. After euthanizing the animals, the organs were removed 
carefully and washed with normal saline prior to weighing. Fig. 39 represents the visceral body 
index of the test animals after necropsy. It was observed that there was a slight increase in liver 
weight when compared to the control group. The highest increase was marked in the case of free 
THP which can be credited to the THP treatment-related hepatocellular hypertrophy. The kidneys 
also showed a slight increase in the organ weight especially in the case of free THP, THP 
nanoparticles as well as in the case of free mTHPC. This increase can be attributed to the tubular 
hypertrophy and may be associated with renal toxicity. The heart and lungs did not show any 
significant weight change and remained unaffected with all the treatments, which proposes the 
non-toxicity and biocompatibility of the formulations.  
 
Figure 39. The visceral body index (%) of untreated group (normal saline) and treated groups 
(free mTHPC, mTHPC-LP, LCNP, THP NP and free THP) performed after sacrificing the 
animals (swiss albino mice) by cervical dislocation. Values are represented as mean ± S.D. 
3.2.12.3 Biochemical analysis 
Biochemical indices are highly sensitive biomarkers to determine the clinical symptoms produced 
by the biological treatments (i.e. formulations). Among these biomarkers, the liver function tests 
(LFTs) and renal function tests (RFTs) are the major indicators of proper liver and kidney 
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functioning respectively. The results of the biochemical analysis of mice blood after being treated 
with formulations are shown below. Aminotransferases are the standard measure of the 
hepatotoxicity. In case of any cellular damage to hepatocytes, alanine aminotransferase (ALT) 
and aspartate aminotransferase (AST) tend to leak out into the blood circulation resulting in the 
increase systemic levels of these enzymes. AST was observed in the highest level in the mice 
treated with free THP and THP loaded PLGA nanoparticles as compared to the mTHPC-LP and 
lipid-coated nanoparticles. The AST level was also slightly higher in the case of free mTHPC 
treated group when compared with the control group but statistically less significant as compared 
to free THP and THP loaded PLGA nanoparticles (Fig. 40). ALT level was also increased in free 
mTHPC and free THP treated groups. These higher levels of both enzymes could be an indication 
of detoxification of the foreign particles and possible liver inflammation. In all other treatment 
groups, no significant change of ALT level was observed. Alkaline phosphatase (ALP) level was 
also significantly increased in all the treatment groups with the highest increase observed in the 
free THP treated group. This could possibly be the indicator of non-alcoholic fatty liver and 
cardiac problems [119]. 
 
Figure 40. Typical liver function tests (LFTs) parameters including (A) ALT, (B) AST and (C) 
ALP levels after being treated with the nanoformulations intravenously. Values are represented 
as mean ± S.D (n=3). 
The results of RFTs (Fig. 41) manifested that the level of uric acid was moderately increased in 
the case of free THP as compared to the controlled group. Contrary to this, the uric acid level was 
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slightly decreased in mTHPC-LP but fell within limits. Moreover, in all other treatment groups, 
the change in the level of these biomarkers remained statistically insignificant. The creatinine 
level was increased with free THP and free mTHPC when compared to the control, yet found 
within the limits. This slight increase in the level of these biomarkers could be a cause of renal 
hypertrophy and poor kidney functioning. With all other treatment groups, there was no 
significant variation in the creatinine level. The results also depicted that the bilirubin level with 
formulations was not altered significantly except for the free THP and mTHPC. The bilirubin 
level was slightly higher in these treatments as compared to the control group but still fell within 
the acceptable limits [120]. The effect of the formulations was also investigated on serum lipid 
profile and total protein level (Fig. 42). There was a significant increase in the cholesterol level 
with all the treatment groups except for mTHPC loaded liposomes but remained well within the 
normal range [121]. The triglycerides level was also found within the normal limit in all the 
treatment groups and no significant changes were observed. There was a slight increase in total 
protein level with free THP, THP NP and free mTHPC treatment but no significant difference 
with mTHPC-LP and LCNP treatment. All these results of the biochemical analysis were also in 
line with the body visceral indices.  
 
Figure 41. Typical renal function tests (RFTs) parameters including (A) creatinine, (B) Bilirubin 
and (C) uric acid levels in mice after being treated with the nanoformulations intravenously. 
Values are represented as mean ± S.D (n=3). 
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Figure 42. Typical lipid profile including (A) cholesterol, (B) triglycerides as well as (C) total 
protein levels after being treated with the nanoformulations intravenously. Values are represented 
as mean ± S.D (n=3). 
3.2.12.4 Hematological analysis 
Any foreign material including drug formulations when coming in contact with blood components 
may induce an acute inflammatory response resulting in complications to the pharmacotherapy. 
This necessitates the complete exploration of the possible toxicity potential of drug formulations 
and their carrier systems on the blood profile [79]. The effect of our nanoformulations on the 
mice's blood and its components was also evaluated through complete blood count (CBC). The 
results for the hematological analysis are presented in Table 8. The results demonstrated that free 
THP damaged the RBCs integrity resulting in decreased total erythrocyte count (TEC) which 
resulted in the reduction of hemoglobin (Hb) level in the blood. TEC and Hb levels were also 
reduced in free mTHPC treated group but less profound as compared to free THP. However, 
mTHPC-LP, LCNP, and THP NP did not significantly affect the RBCs level when compared with 
the control (blank) group. These observations were also in accordance with the previous results 
obtained during the ex vivo hemolysis assay. Total leukocyte count (TLC) was also remarkably 
affected during treatment with free THP which can lead to neutropenia [121]. This may be caused 
by bone marrow suppression resulting in a delayed inflammatory response. Free mTHPC also 
reduced the TLC but the effect was less intense as compared to free THP. These results call for 
the encapsulation of the free THP/mTHPC into relatively nontoxic carrier systems. The mTHPC-
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LP, THP NP and LCNP did not show a significant effect on WBCs. Other parameters including 
mean corpuscular volume (MCV), Hematocrit (HCT), mean corpuscular hemoglobin (MCH), 
mean corpuscular hemoglobin concentration (MCHC), platelets count and mean platelet volume 
(MPV) were also monitored and it was observed that all these parameters remained more or less 
unchanged in all the nanoformulations, depicting the safety of these formulations.  
Table 8. The changes in biochemical parameters in the blood serum of albino mice after 
intravenous administration of free mTHPC, mTHPC loaded liposomes, LCNP, THP PLGA 
nanoparticles, free THP, and normal saline into the tail vein. After 7 days of treatment, blood was 
withdrawn from the mice and complete blood count was performed. The values are expressed as 
mean ± S. D (n = 3).   
Biomarker 
Free 
mTHPC 
mTHPC-LP LCNP THP NP Free THP Blank  
TEC (1012/L) 5.9 ± 1.6 7.0 ± 1.6 6.4 ± 1.7 6.2± 1.2 5.4 ± 1.8 6.7 ± 1.9 
Hb (g/dL) 10.2 ± 1.8 10.5 ± 2.1 10.7 ± 1.6 10.7 ± 2.2 9.8 ± 1.9 10.9 ± 1.8 
MCV (fL) 52.3 ± 5.4 54.7 ± 4.8 59.6 ± 5.4 55.5 ± 6.0 51.2 ± 5.5 58.3 ± 4.2 
HCT (%) 31.6 ± 4.6 33.5 ± 5.3 32.1 ± 5.1 31.5 ± 3.9 30.8 ± 6.0 32.4 ± 5.6 
MCH (pg) 16.5 ± 2.3 17.4 ± 2.6 16.8 ± 3.5 17.6 ± 2.7 18.4 ± 3.4 16.3 ± 4.1 
MCHC (%) 34.7 ±2.8 33.8 ± 3.1 33.1 ± 1.7 34.6 ± 2.6 30.1 ± 2.9 33.6 ± 3.6 
TLC (109/L) 8.7 ± 2.4 9.2 ±3.7 9.7 ± 3.9 8.9 ± 2.5 8.2 ± 2.7 9.4 ± 3.5 
Platelets (109/L) 705 ± 19 714 ± 27 738 ± 21 726 ± 28 693 ± 22 758 ± 25 
MPV (fL) 8.0 ± 1.6 7.7 ± 2.0 7.6 ± 1.8 7.9 ± 2.1 8.4 ± 2.1 7.5 ± 1.9 
3.2.12.5 Erythrocyte adhesiveness /aggregation test (EAAT) 
The erythrocyte aggregation assay is a sensitive biomarker to detect the presence of low grade, 
smoldering and subclinical inflammation. The degree of erythrocyte adhesiveness/aggregation 
correlated significantly with the presence of enhanced concentrations of the inflammation-
sensitive plasma proteins (i.e. fibrinogen) which are directly involved in the erythrocyte 
aggregability. In our study, EAAT was carried out to check the ex vivo behavior of the 
nanoformulations on the red blood cells (RBCs) (Fig. 43). It was evident from the assay that the 
RBCs treated with free drugs (i.e. free mTHPC and free THP) as well as THP loaded nanoparticles 
showed slight changes in the overall structure and morphology in the erythrocytes. However, the 
changes were not to an extent to damage the RBCs morphology completely. In contrast to the free 
drugs, mTHPC-LP and LCNP did not induce any aggregation effect. These results were in 
correlation with the results of the hematological analysis which showed a small decrease in the 
erythrocytes counts when treated with free mTHPC, free THP or THP loaded PLGA 
nanoparticles. Based on these observations, it was inferred that our nanoformulations have very 
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slightly affected the erythrocytes and can be considered a biocompatible as the EAAT index was 
still within the acceptable limits [81, 122]. 
 
Figure 43. Ex vivo erythrocytes aggregation assay after treatment with the nanoformulations (free 
mTHPC and mTHPC liposomes at a dose equivalent to 0.150 mg kg-1 body weight; free THP 
and THP NP at a dose equivalent to 5 mg kg-1 body weight, while the LCNP was a administered 
at a combined dose of both mTHPC/THP) with 100 μl of erythrocytes suspension (2% v/v) 
compared to untreated cells.  
3.2.12.6 Histopathological examinations 
One of the major problems associated with the clinical use of the anticancer agents (e.g. 
chemotherapeutics and photosensitizers) is the injuries on the peripheral tissues which can lead to 
multiple organ toxicity [48]. In order to examine any toxicity to mice organs after being treated 
with our nanoformulations, the biochemical analysis was accompanied by histological studies. 
The histological slide of vital organs (i.e. heart, liver, kidney, and lungs) was prepared through 
the rotary microtome. The tissue sectioned were fixed on glass slides, stained with H&E stain and 
observed under the microscope (Fig. 44). For the H & E staining, the cell nucleus was stained 
blue with hematoxylin while the cell cytoplasm and extracellular matrix were stained pink by 
eosin. Normal cells appeared polygonal in shape with blue nuclei in spherical or spindle shape. 
The cytoplasm of the necrotic cells became pink amorphous material with their nucleus 
disappeared. Whereas the apoptotic cells shrank and turned round with the nucleus condensed and 
became darker [123]. The images of the tissue sections are presented in Fig. 44. From the figure, 
it can be observed that heart samples from all treatment groups appear to be completely normal. 
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There are no visible signs of inflammation, necrosis or hyperthermia. The structure of the liver 
was also found to be normal and no changes in fat tissues were seen except for free THP. The free 
THP treated group showed some signs of the apoptotic cells with fibrosis, pyknosis and hepatic 
lesions [124].  No evidence of the necrotic bodies or hydrophobic degradation was found in any 
of the treatment groups. Kidney showed the signs of necrosis, apoptosis, as well as congestion of 
the renal tissue in the free THP and THP NP, treated groups while other treatment groups 
remained unaffected. Moreover, small changes in the lung’s histology with the breakage of the 
lung’s fiber were also noticeable in free THP and THP NP treated groups [123]. In all the other 
treatment groups, normal alveolar and arteriolar structures were observed. These findings 
confirmed the safety of our lipid coated particles as no evidence of the toxicity was visible in any 
of histological studies. 
 
Figure 44. Histopathological analysis of various organs after treatment with free mTHPC, 
mTHPC-LP, THP NP, LCNPs and free THP. The animals treated with normal saline were taken 
as control (Blank). The tissues were stained with hematoxylin/eosin to assess the potential effects 
of treatments on the organ’s morphology and cellular damage. 
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4.1 Summary and outlook 
The main theme of the present work was the development of a novel nanocarrier system that can 
deliver two different therapeutics modalities to the cancer cells. Such a nanocarrier is superior to 
conventional drug delivery system as it combines two different approaches (i.e. chemotherapy 
and photodynamic therapy) within one carrier system to treat the cancer. In this work, we were 
interested in lipid enveloped biodegradable nanoparticles termed as lipoparticles in which two 
hydrophobic drugs could be encapsulated in separate compartments, a chemotherapeutic agent 
(Pirarubicin, THP) in the nanoparticle core and a photosensitizer (Temoporfin, mTHPC) in the 
lipid bilayer shell. Such a system not only increases the therapeutic efficacy, circulating time and 
bioavailability of the drugs but also reduce the drug leakage and side effects to the other body 
tissues. 
In the introduction part of the thesis deals with back ground of the basic principles and detailed 
mechanism of the photodynamic therapy. The ideal properties of the photosensitizers were 
discussed. This was followed by a brief insight into the nanocarriers including the liposomes, 
polymeric nanoparticles and lipid-polymer hybrid nanoparticles. Different methods to prepare the 
lipoparticles have also been discussed. 
The methodology section of the thesis deals with the preparation of mTHPC loaded liposomes, 
THP loaded nanoparticles and consequently the lipid enveloped polymeric nanoparticles. The 
formed nanoformulations were then evaluated in terms of physicochemical characterizations, in 
vitro, in ovo, in vivo as well as the biocompatibility studies. 
In results section, the encapsulation of mTHPC, a potent 2nd generation PS in the liposomes was 
discussed. For this purpose, a broad range of lipid combination was explored. The 
physicochemical characterizations including size distribution, zeta potential and encapsulation 
efficiency was performed. Surface morphological studies using the at atomic force microscopy 
and cryogenic transmission electron microscopy was conducted. The results obtained from these 
studies were found to be in accordance with the previous results obtained from the zeta sizer 
measurement. Further investigations including quantitative assessment of the reactive oxygen 
species and cellular photodynamic therapy at different wavelengths and different light doses have 
been discussed. In order to minimize the unethical use of the animals, chick chorioallantoic 
membrane model (in ovo) as an alternative in vivo model was elaborated for the vascular targeted 
photodynamic therapy. The intracellular uptake studies using confocal laser scanning microscopy 
was performed and an effective cellular uptake in the perinuclear region have been shown.  
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In the next chapter of the results, the encapsulation of THP loaded PLGA nanoparticles have been 
discussed. Two different size of nanoparticles (200nm and 400nm) were prepared in order to have 
a comparative evaluation of the nanoparticles size, polydispersity index as well as the cell viability 
using dynamic light scattering and MTT assay respectively. In vitro drug release in simulated 
conditions revealed a biphasic drug release pattern with initial burst release phase followed by the 
sustained released pattern for the following days. The THP nanoparticles with smaller size 
(200nm) showed a higher drug release as compared to 400nm THP NP which was attributed to 
the larger available surface area for drug diffusion in the earlier case. 
Further in the results section, the preparation of the lipoparticles have been discussed. Based on 
the preliminary studies, two best performing liposomes DPPC/mPEG-DPPE5000 and DPPC/DPPG 
were combined to form a single liposome i.e. DPPC/DPPG/mPEG-DPPE5000 and was coated over 
the 200nm THP nanoparticles. The formed lipoparticles were also subjected to physicochemical 
characterizations. An increase in the lipoparticles size of 4-5 nm as compared to uncoated 
nanoparticles was perceived which was also confirmed with the surface morphological studies 
using AFM and TEM. The determination higher therapeutic efficacy of the lipoparticles by in 
vitro cytotoxicity synergism and ROS assay has also been described. The lipoparticles did not 
show any genotoxicity has been elaborated using single cell gel electrophoresis (comet assay). 
The stability of the lipoparticles was established in simulated physiological conditions (60% 
serum & PBS 7.4) and small reduction in particles size owing to the presence of protein corona 
was demonstrated. 
Biocompatibility studies were also performed to validate the compatibility of the lipoparticles 
with the blood components. Hemolysis assay, activated partial thromboplastin time and 
erythrocyte aggregation assay confirmed the non-toxic and biocompatible nature of the 
lipoparticles. After the evidencing the biocompatibility of the lipoparticles, the acute in vivo 
toxicity assessment was performed using BALB/c mice. No significant changes in the body 
visceral index and serum biomarkers was observed.  Also, no significant changes in the tissue 
histopathology was observed. 
On the basis of all of these finding, it can be concluded that development of such a novel 
nanocarrier system can be employed for simultaneous delivery of the multiple drugs to the cancer 
cells with minimum toxicity. Future pharmacokinetic profiling with in vivo biodistribution and in 
vivo tumor models with targeting ligands (e.g. antibodies, aptamer etc.) attached on the 
lipoparticles can serve as a critical link for the pre-clinical studies.  
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4.2 Zusammenfassung und Ausblick 
Das Hauptthema der vorliegenden Arbeit war die Entwicklung eines neuartigen Nanocarrier-
systems, das zwei verschiedene Therapieansätze zur Krebsbehandlung vereint. Ein solcher 
Nanocarrier ist dem herkömmlichen Drug Delivery System überlegen, da er verschiedene Ansätze 
(z.B. Chemotherapie und photodynamische Therapie) innerhalb eines Trägersystems kombiniert. 
In dieser Arbeit lag der Fokus auf Lipid umhüllte, biologisch abbaubare Nanopartikel, die als 
„Lipopartikel“ bezeichnet werden. Hierbei ist es möglich, zwei hydrophobe Arzneistoffe in 
getrennten Bereichen des Trägersystems zu verkapseln: ein Chemotherapeutikum (Pirarubicin, 
THP) im Nanopartikelkern und ein photoaktiver Stoff (Temoporfin, mTHPC) in der Lipid-
Doppelschicht. Ein solches System erhöht nicht nur die therapeutische Wirksamkeit, die 
Blutzirkulationszeit und die Bioverfügbarkeit der Arzneimittel, sondern reduziert auch den 
frühzeitigen Austritt des Arzneistoffes sowie Nebenwirkungen auf andere Gewebe. 
In der Einleitung der Arbeit werden die Grundprinzipien und der detaillierte Mechanismus der 
photodynamischen Therapie dargestellt. Das Eigenschaftenprofil wie auch deren Optimierung 
solcher photoaktiven Stoffe, der sogenannten „Photosensitizer“, standen hier im Vordergrund der 
Diskussion. Im Anschluss erfolgte eine systematische Präsentation nanoskaliger „drug delivery“ 
Systeme, einschließlich Liposomen, polymerer Nanopartikel und Lipid-Polymer-Hybrid-
Nanopartikel. Verschiedene Methoden zur Herstellung der modernen Lipopartikel wurden 
ebenfalls dargestellt und diskutiert. 
Der experimentelle Teil der Dissertation umfasst die Herstellung mTHPC-beladener Liposomen, 
THP-beladener Nanopartikel und Lipid umhüllter Polymernanopartikel. Die Charakterisierung 
der hergestellten parenteralen Formulierungen erfolgte mit Hilfe von physikalisch-chemischen 
Methoden, in vitro, in ovo, in vivo sowie mit toxikologischen Biokompatibilitätsstudien. 
Der Ergebnisteil beschreibt ausführlich die verwendeten Methoden und Analyse der 
Verkapselung von mTHPC, dem verwendeten potenten Photosensitizer der 2. Generation, in 
Liposomen. Zu diesem Zweck wurde ein breites Spektrum an Lipidkombinationen getestet und 
mit physikalisch-chemischen Methoden einschließlich Größenverteilung, Zetapotenzial sowie 
deren Verkapselungseffizienz untersucht. Durch Rasterkraftmikroskopie (AFM) und Gefrier-
Transmissionselektronenmikroskopie konnte die Teilchengröße wie auch deren 
Oberflächenmorphologie analysiert werden. Die Ergebnisse dieser Studien bestätigten die 
Ergebnisse der PCS-Messungen. Weitere Untersuchungen wie die quantitative Bewertung der 
während der biologischen Untersuchungen entstandenen reaktiven Sauerstoffspezies sowie die 
Wirkung der in Zellkultur durchgeführten photodynamischen Therapie, bei verschiedenen 
Wellenlängen und Lichtstärken, wurden diskutiert. Um die unethische Nutzung von 
Versuchstieren zu minimieren, erfolgte die Untersuchung der gezielten antivaskulären 
(antiangiogenese Therapie) photodynamischen Therapie an dem chorioallantoischen 
Membranmodell (CAM, in ovo), das eine Alternative zum in vivo Modell darstellt. Die Aufnahme 
der Wirkstoffträger in die Zellen erfolgte mit Hilfe der konfokalen Laserscanning-Mikroskopie 
und verdeutlichte eine effektive zelluläre Aufnahme in den perinukleären Bereich. 
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Das folgende Kapitel des Ergebnisteils beschäftigt sich mit der Verkapselung von THP in PLGA-
Nanopartikel. Zwei verschiedene Größen von Nanopartikeln (200nm und 400nm) wurden 
hergestellt, um eine vergleichende Bewertung der Größe der Nanopartikel und des 
Polydispersitätsindex auf das Zellüberleben zu erhalten. Diese Daten konnten mittels dynamischer 
Lichtstreuung bzw. MTT-Assay erhalten werden. Die in vitro Freisetzung des Arzneistoffes unter 
simulierten Bedingungen ergab ein zweiphasiges Freisetzungsprofiel, mit einer anfänglichen 
Burst-Freisetzungsphase, gefolgt von einer über die folgenden Tage anhaltenden kontinuierlichen 
Freisetzung. Die THP-Nanopartikel mit geringerer Größe (200 nm) zeigten dabei eine höhere 
Wirkstofffreisetzung pro Zeiteinheit im Vergleich zu 400 nm großen THP Nanopartikeln, was als 
eine Folge der größeren verfügbaren Oberfläche für die Wirkstoffdiffusion diskutiert werden 
kann. 
Basierend auf den Voruntersuchungen wurden im nächsten Kapitel die beiden leistungsstärksten 
Liposomen zu einem einzigen Liposom mit der Zusammensetzung DPPC/DPPG/mPEG-
DPPE5000 kombiniert. Diese Liposomen sind anschließend zur Beschichtung der 200nm großen 
THP-Nanopartikel verwendet worden. Diese wurden eingehend physikalisch-chemisch 
charakterisiert. Die Lipopartikelgröße nimmt um etwa 4-5 nm im Vergleich zu unbeschichteten 
Nanopartikeln zu, was auch die oberflächenmorphologischen Studien mit AFM und TEM 
bestätigten. Die Bestimmung der höheren therapeutischen Wirksamkeit der Lipopartikel durch 
Zytotoxizitätsstudien wurde in vitro betätigt. Der Nachweis der erhöhten Produktion reaktiver 
Sauerstoffspezies erfolgte ebenfalls. Die Einzelzellgelelektrophorese (Comet-Assay) gab 
keinerlei Hinweise auf eine Genotoxizität der Lipopartikel. Die Untersuchung der Stabilität der 
Lipopartikel fand unter simulierten physiologischen Bedingungen (60% Serum, PBS 7,4) statt 
und zeigte eine geringe Vergrößerung des Partikeldurchmessers durch das Vorhandensein einer 
Proteinkorona. 
Durch Biokompatibilitätsstudien war es möglich, die Verträglichkeit der Lipopartikel mit 
Blutkomponenten zu validieren. Die Bestimmung der aktivierten Teilthromboplastinzeit und 
Erythrozytenaggregationstests bestätigten die Verträglichkeit und Biokompatibilität der 
Lipopartikel. Anschließend konnte die in vivo Toxizität der Lipidpartikel an BALB/c-Mäusen 
stattfinden. Es wurden keine signifikanten Veränderungen im viszeralen Index der Mäuse und in 
den Serum-Biomarkern beobachtet. Die Gewebehistopathologie zeigte ebenfalls keine 
signifikanten Veränderungen. 
Auf der Grundlage all dieser Ergebnisse kann der Schluss gezogen werden, dass es möglich ist, 
solche neuartigen Nanocarriersystems für die gleichzeitige Abgabe verschiedener Arzneistoffe an 
Krebszellen mit minimaler Toxizität prinzipiell einzusetzen. Die zukünftige Erstellung des 
pharmakokinetischen Profils einschließlich der in vivo Biodistribution und die Überprüfung der 
Effektivität der Lipopartikel an in vivo Tumormodellen können als kritisches Bindeglied für 
präklinische Studien dienen. Auch durch eine Kopplung von Liganden (z.B. Antikörpern, 
Aptameren etc.) kann eine weitere Steigerung der Effizienz erreicht werden. 
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